| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Pre-clinical data readout example | Pre-clinical | — | Subscribe to access the data. | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
Lexaria Bioscience Corp.$0.65
+0.06 (+8.94%)
F 9Pipeline Score Pharma · Pre-Clinical
Market Cap
16.11 M
EPS
-0.48
P/E Ratio
-
Value Trade
36.51 K
SEC Financials
Q1 2026Dilution Risk
Revenue
20.00 K
R&D Expenses
475.39 K
Total Assets
6.49 M
Total Liabilities
277.00 K
Equity
6.60 M
D/E Ratio
12,345
4.5 %
Week
-30.85 %
1 Month
-1.52 %
3 Month
-42.98 %
6 Month
-87.8 %
5 Year
-94.04 %
All Time
Cash Data
Cash Position
5.24 M
Monthly Burn
484.00 K
Runway
8.1 mo
Burn Trend
SEC Filing
Apr 13, 2026
Overview
Volume
55.35 K
52 Week Range
0.46 - 1.55
% held by Insiders
2.96 %
% held by Institutions
6.01 %
Enterprise Value
10.54 M
Total Shares
24.90 M
Short %
1.43 %
Float Shares
24.05 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lexaria Bioscience Corp.
290Total events
0Upcoming
69Tier-1 (high impact)
2012 – 2025Coverage
Event history 290
Dec 15, 2025
▼Equity OfferingCorporate
Registered direct offering of 2,661,600 shares at $1.315 per share, with warrants
Sep 26, 2025
▼Equity OfferingCorporate
Registered direct offering of 2,666,667 shares at $1.50 per share for $4.0 million gross proceeds
Apr 25, 2025
▼Equity OfferingCorporate
Lexaria announces $2 million registered direct offering of common stock
Q1 2025
◆Trial InitiationDehydraTECH-CBDTrial
Phase 1b hypertension study likely to begin in first half of 2025
hypertensionsource ↗
2025
◆Trial InitiationDehydraTECH-GLP-1Trial
Australian-registered Phase 1b DehydraTECH-GLP-1 diabetes and weight-loss study to begin
diabetes and weight losssource ↗
Oct 16, 2024
Sep 5, 2024
◆Management ChangeCorporate
CEO transition: Chris Bunka steps down, Richard Christopher appointed as new CEO
Jul 17, 2024
▲Interim AnalysisTrial
Positive interim body weight results from first four weeks of dosing in diabetes animal study
diabetessource ↗
Jul 17, 2024
Mar 1, 2024
▲IND ClearanceDehydraTECH-CBDIND
FDA clearance for Phase 1b hypertension trial with DehydraTECH-CBD
hypertensionsource ↗
Feb 15, 2024
▼Equity OfferingCorporate
Registered direct offering of 1,558,443 shares at $2.31 per share for gross proceeds of $3.6 million
Drug Pipeline Intelligence
F9
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 6%
Micro Cap (rank 857 of 911)
Percentile RankLexaria Bioscience Corp. has significant pipeline risk (9/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
liraglutide | diabetes | — | 2024-07-17 | body weight gain: initial acclimation 10.9%, dehydra TECH liraglutide weight loss -1.58%, dehydra TECH CBD3 weight loss -1.50%; weight loss 5 percent: only in Study arms A, B, C, and E Read More | Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC t Read More | |
liraglutide | diabetes | — | 2024-07-17 | body weight gain: initial acclimation 10.9%, dehydra TECH liraglutide weight loss -1.58%, dehydra TECH CBD3 weight loss -1.50%; weight loss 5 percent: only in Study arms A, B, C, and E Read More | Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC t Read More | |
liraglutide | diabetes | — | 2024-07-17 | body weight gain: initial acclimation 10.9%, dehydra TECH liraglutide weight loss -1.58%, dehydra TECH CBD3 weight loss -1.50%; weight loss 5 percent: only in Study arms A, B, C, and E Read More | Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC t Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LEXX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LEXX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LEXXLexaria Updates Business Development
Lexaria Bioscience Corp. reported successful meetings with various pharmaceutical partners at the 2026 BIO International Convention. The company is focusing on advancing existing relationships while exploring new opportunities, particularly in the GLP-1 sector. There is a notable shift towards drug safety and tolerability among industry players. Additionally, interest in Lexaria's DehydraTECH technology is expanding beyond its initial applications.
Read more →LEXXLexaria’s Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
Lexaria Bioscience Corp. has commenced dosing for its Human Pilot Study #7, evaluating its DHT-sema compositions against Novo Nordisk's Wegovy tablets. The study aims to assess safety, tolerability, and pharmacokinetic properties over five weeks. Lexaria is implementing new enhancements in its formulations, including the use of oral tablets for the first time. Results are anticipated to attract interest from the pharmaceutical industry.
Read more →LEXXLexaria’s Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
Lexaria Bioscience Corp. has commenced dosing for its Animal Study #1 (GLP-1-A26-1) on schedule, focusing on enhancing drug formulations using DehydraTECH technology. The study aims to evaluate new formulations against existing standards and has already led to the filing of three new patent applications. Results are expected by early September 2026.
Read more →LEXXGLP-1 ‘Arms Race’ Intensifies as the Addressable Markets Continue to Expand
Lexaria Bioscience Corp. reports a surge in GLP-1 drug prescriptions, particularly for weight loss, with over three million Wegovy prescriptions filled since January 2026. The company highlights the expanding indications for GLP-1 drugs, including obesity-related conditions. Additionally, Lexaria's DehydraTECH technology aims to improve drug delivery and reduce side effects, positioning the company favorably in a competitive market.
Read more →LEXXLexaria’s Animal Study Examining Next-Generation GLP-1 drugs is Underway
Lexaria Bioscience Corp. has completed dosing in its 2026 Animal Study evaluating the compatibility of its DehydraTECH technology with next-generation GLP-1 drugs, retatrutide and amycretin. The study aims to explore improved oral dosing formulations and assess pharmacokinetic performance. If successful, it could expand the applicability of DehydraTECH and establish new intellectual property claims.
Read more →LEXXLexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
Lexaria Bioscience Corp. is set to attend the BIO International Convention in San Diego from June 22-25, 2026. The company's participation follows a successful attendance at last year's event, which catalyzed its business development program. Lexaria is experiencing heightened interest in its DehydraTECH platform, leading to numerous collaborative discussions with various industry players.
Read more →LEXXLexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
Lexaria Bioscience Corp. has received ethics approval for its Human Pilot Study #7, which will evaluate its DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets. The study aims to assess safety, tolerability, and pharmacokinetic performance over five weeks. Lexaria's advancements in oral drug delivery could lead to significant commercial opportunities in the pharmaceutical industry.
Read more →LEXXLexaria Bioscience Releases Second Episode of Investor Video Series
Lexaria Bioscience Corp. has released the second episode of its investor video series featuring CEO Rich Christopher. The episode discusses the extension of a Material Transfer Agreement with a pharmaceutical partner until the end of 2026 and outlines the company's research priorities for GLP-1. Lexaria aims to enhance its clinical evidence and expand partnerships within the drug delivery sector.
Read more →LEXXLexaria Updates Progress on Human Study #7
Lexaria Bioscience Corp. has provided an update on its Human Pilot Study #7, which will evaluate two new oral DHT-sema compositions against Novo Nordisk's Wegovy tablets. The company has submitted requests for ethics approval and completed laboratory work for the study. The five-week study aims to assess safety, tolerability, and pharmacokinetic properties, with dosing expected to begin in mid-June.
Read more →LEXX▲ +7.9%on this newsshared move
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Lexaria Bioscience Corp. has launched an investor video series called 'Reformulated: Into the Mainstream' to enhance communication with shareholders. The inaugural episode features CEO Rich Christopher discussing the DehydraTECH platform and its relevance to the GLP-1 market, which saw $75 billion in revenue in 2025. The series aims to provide ongoing insights into the company's strategies and developments.
Read more →LEXX▼ -21.9%on this newsshared move
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Bioscience Corp. has successfully extended its Material Transfer Agreement with a pharmaceutical company until December 31, 2026. This extension allows for further evaluation of Lexaria's DehydraTECH technology in pre-clinical settings, particularly related to GLP-1. The company has made significant progress in its GLP-1 development program, with results expected in the latter half of 2026.
Read more →LEXXLexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Lexaria Bioscience Corp. has initiated Animal Study #2 to evaluate the compatibility of next-generation GLP-1 drugs, amycretin and retatrutide, with its DehydraTECH technology. The study aims to improve drug absorption and reduce side effects. Dosing is expected to start within 30 days, and the study is fully funded by corporate resources.
Read more →LEXXLexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
Lexaria Bioscience Corp. reports significant growth in the GLP-1 oral pill market, particularly with the Wegovy® pill, which has seen over 600,000 prescriptions written in its first two months. The company anticipates that oral GLP-1 drugs could capture a substantial market share, potentially reaching $60 billion by the mid-2030s. Lexaria's DehydraTECH™ technology is positioned to enhance the effectiveness of these drugs.
Read more →LEXXLexaria’s New Animal Study Aims to Expand Valuable Intellectual Property
Lexaria Bioscience Corp. has engaged a contract research organization to conduct an animal study evaluating new formulations of its DehydraTECH technology. The study aims to explore enhanced performance of GLP-1 compositions and potentially secure new intellectual property claims. Dosing is expected to begin within 60 days, leveraging historical data for comparison.
Read more →LEXX▼ -6.6%on this news
Lexaria Applauds Eli Lilly’s Foundayo™ Drug Approval
Lexaria Bioscience Corp. applauds the FDA's approval of Eli Lilly's Foundayo, an oral GLP-1 agonist for weight management. This approval expands treatment options for obesity, potentially benefiting Lexaria's DehydraTECH technology aimed at reducing side effects. However, Foundayo has reported higher adverse effects compared to existing treatments.
Read more →LEXX▲ +11%on this news· ran to +33% by day 1shared move
Lexaria to Begin New Human Clinical Study in GLP-1
Lexaria Bioscience Corp. has announced the initiation of Human Pilot Study #7 to evaluate its DehydraTECH-semaglutide compositions against Wegovy tablets. The study will assess safety, tolerability, and pharmacokinetics over five weeks using a new oral tablet formulation. Contracts with a CRO have been signed, and ethics approval is being sought. Positive results could enhance Lexaria's appeal to pharmaceutical partners.
Read more →LEXXLexaria’s Robust Patent Portfolio Continues to Grow
Lexaria Bioscience Corp. has announced the granting of 5 new patents, including two for diabetes treatments utilizing GLP-1 drugs. The patents enhance Lexaria's intellectual property portfolio and reflect its ongoing commitment to research and development. The company is optimistic about future patent awards and the potential of its DehydraTECH technology in drug delivery.
Read more →LEXX▲ +7.1%on this newsshared move
Lexaria’s Oral GLP-1 Drug Strategy Validated by Industry
Lexaria Bioscience Corp. is advancing its oral GLP-1 drug strategy, responding to patient preferences for oral delivery over injections. The company is in discussions with major pharmaceutical firms and has made proprietary advancements in its DehydraTECH platform. The GLP-1 market is projected to grow significantly, with oral formulations expected to capture a substantial share. However, challenges remain, including high discontinuation rates due to gastrointestinal side effects.
Read more →LEXX▲ +5%on this news
Lexaria Announces New R&D Plans for 2026
Lexaria Bioscience Corp. has announced its 2026 R&D Program, focusing on enhancing pharmaceutical opportunities through new formulations. The program includes a human study comparing DehydraTECH-semaglutide formulations to existing products, and two animal studies aimed at testing new drug delivery methods. The company anticipates starting recruitment for the human study in April 2026, with results expected by Q4 2026.
Read more →LEXX▼ -8.7%on this news
Lexaria Announces Positive Final Results From Human Pilot Study #5
Lexaria Bioscience Corp. announced positive final results from Human Pilot Study #5, which compared its oral DehydraTECH-liraglutide (DHT-LIR) capsules to injected Saxenda (SAX-LIR). The study achieved its primary safety and tolerability endpoint, showing a 22.7% reduction in adverse events with DHT-LIR. The results support the pursuit of an oral liraglutide product, potentially addressing an unmet market need.
Read more →LEXXLexaria Awarded Six Additional Patents
Lexaria Bioscience Corp. has announced the granting of six additional patents, bringing its total to 60 worldwide. This expansion includes important patents in Australia and the European Union, particularly in the fields of nicotine delivery, hypertension, epilepsy, and diabetes treatments. The company encourages shareholders to vote at the upcoming 2026 Annual Meeting.
Read more →LEXXLexaria Releases Annual Letter from the CEO
Lexaria Bioscience Corp. has released its Annual Letter from CEO Richard Christopher, highlighting significant advancements in its DehydraTECH technology for oral drug delivery in the GLP-1 sector. The company completed its first Phase 1b study in Australia and achieved positive results across various studies. Lexaria also raised $9.5M in funding to support its 2026 plans, despite facing challenges in the competitive market and stock price fluctuations.
Read more →LEXXLexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
Lexaria Bioscience Corp. has released additional results from its Phase 1b study GLP-1-H24-4, indicating positive outcomes for its DehydraTECH platform. The study showed comparable safety and efficacy to the Rybelsus control, with notable reductions in adverse events. Participants using DHT-semaglutide reported better health outcomes, while DHT-CBD demonstrated significant blood pressure reductions. Lexaria plans to further investigate these findings in future studies.
Read more →LEXXPrimary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4
Lexaria Bioscience Corp. announced the successful achievement of the primary endpoint in its Phase 1b study of DehydraTECH-semaglutide, which demonstrated a 48% reduction in overall side effects compared to Rybelsus. The study also showed a 55% reduction in gastrointestinal side effects. Recent financing activities have provided Lexaria with the necessary funds to explore new development opportunities through 2026.
Read more →LEXX▼ -18.9%on this news
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. has successfully closed a registered direct offering, raising approximately $3.5 million by selling 2,661,600 shares at $1.315 each. Concurrently, the company issued unregistered warrants for the same number of shares at an exercise price of $1.19. The proceeds will be used to enhance research and development and support general corporate activities.
Read more →LEXX▼ -33.6%on this news· ran to -49% by day 3shared move
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. has announced a registered direct offering of 2,661,600 shares at $1.315 per share, expected to raise approximately $3.5 million. The company plans to use the proceeds for research and development, working capital, and general corporate purposes. The offering is set to close around December 16, 2025, pending customary conditions.
Read more →LEXX▼ -33.6%on this news· ran to -49% by day 3shared move
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Kelowna, BC / ACCESS Newswire /
Lexaria Bioscience Corp. has announced a $3.5 million registered direct offering priced at $1.315 per share. The offering involves 2,661,600 shares and includes unregistered warrants for the same number of shares, priced at $1.19 each. The funds will be directed towards advancing the company's research and development initiatives and for other operational needs. The closing of the offering is anticipated to occur on December 16, 2025, pending customary conditions.
Read more →LEXXLexaria Bioscience Corp. Provides Strategic Update
Lexaria Bioscience Corp. has announced a strategic update, including the engagement of a global business development advisory firm to enhance its outreach in the pharmaceutical sector. The company has also secured four new patents related to its DehydraTECH technology, which aims to improve drug delivery. Recent equity financing of $4 million will support expanded R&D activities into 2026. Lexaria anticipates results from its Phase 1b study in the GLP-1 sector, focusing on patient safety and efficacy.
Read more →LEXXLexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. has completed a registered direct offering, raising $4.0 million by selling 2,666,667 shares at $1.50 each. The proceeds will support the company's R&D and business development plans for 2026. Additionally, unregistered warrants for the same number of shares were issued. H.C. Wainwright & Co. served as the placement agent.
Read more →LEXX▼ -31.4%on this newsshared move
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. has announced a registered direct offering of 2,666,667 shares priced at $1.50 each, aiming to raise approximately $4.0 million. The offering includes unregistered warrants for the purchase of additional shares. Proceeds will be used for working capital and general corporate purposes. The closing is expected around September 29, 2025.
Read more →LEXX▼ -31.4%on this newsshared move
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Kelowna, BC / ACCESS Newswire /
Lexaria Bioscience Corp. has announced a definitive agreement for a registered direct offering priced at $1.50 per share, aiming to raise $4.0 million. The offering will involve the sale of approximately 2,666,667 shares and will be managed by H.C. Wainwright & Co. The proceeds from this offering are intended for working capital and general corporate purposes. The offering is expected to close around September 29, 2025, subject to customary conditions.
Read more →LEXXLexaria’s Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Lexaria Bioscience Corp. announced successful results from a study demonstrating that its DehydraTECH technology enhances the brain biodistribution of semaglutide compared to conventional formulations. The study found significant improvements in the apparent distribution of semaglutide in key brain regions, suggesting potential benefits in safety and efficacy for GLP-1 drugs. These findings support further research and potential partnerships in the biopharma industry.
Read more →LEXXLexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
Lexaria Bioscience Corp. will participate in the 27th Annual H.C. Wainwright Global Investment Conference from September 8-10, 2025. CEO Richard Christopher will present and be available for investor meetings. The presentation will be accessible for remote viewing starting September 5, 2025. Lexaria's DehydraTECH technology enhances drug delivery through oral means.
Read more →LEXXLexaria’s Phase 1b GLP-1 Study Achieves Important “Last Patient Last Visit” Milestone
Lexaria Bioscience Corp. has announced the completion of the 'Last Patient Last Visit' milestone in its Phase 1b GLP-1 study in Australia. This milestone marks the end of patient dosing and clinical testing, with data analysis currently underway. The study aims to evaluate the safety and efficacy of various DehydraTECH formulations compared to a control arm using Rybelsus. Positive interim results have been reported, showing promising safety and tolerability outcomes.
Read more →LEXXGLP-1 “Arms Race” Broadens to Include Dozens of Companies
Lexaria Bioscience Corp. is positioning its DehydraTECH technology to enhance drug absorption and reduce gastrointestinal side effects associated with GLP-1 drugs. The GLP-1 market is growing rapidly, with 39 new drugs in development by various companies. Major pharmaceutical firms are actively engaging in collaborations and acquisitions to strengthen their positions in this expanding market.
Read more →LEXX▼ -8.5%on this news
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
Lexaria Bioscience Corp. has reported positive interim results from its Phase 1b study of DehydraTECH-semaglutide, showing significant reductions in side effects compared to Rybelsus. The study indicates a 36.5% decrease in overall adverse events and a 43.5% reduction in gastrointestinal side effects. However, the results are based on an 8-week interim analysis, and further data will be needed for conclusive efficacy assessments.
Read more →LEXX▲ +6.2%on this newsshared move
Lexaria’s DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
Lexaria Bioscience Corp. has highlighted its DehydraTECH technology as a solution to reduce side effects in the rapidly growing GLP-1 pharmaceutical sector. With the industry projected to generate over $156 billion by 2030, Lexaria aims to attract pharmaceutical partnerships to enhance drug delivery and patient retention. The technology addresses significant gastrointestinal adverse effects, which have led to high discontinuation rates among users.
Read more →LEXXLexaria Reaches Patent Milestone – 50 Patents Now Granted Worldwide
Lexaria Bioscience Corp. has announced the granting of two new international patents, bringing its total to 50 worldwide. These patents enhance the company's intellectual property for treating epilepsy and sublingual nicotine delivery. CEO Rich Christopher emphasized the importance of this milestone for future commercial opportunities and shareholder value. The epilepsy drug market is expected to grow significantly in the coming years.
Read more →LEXXLexaria’s DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Lexaria Bioscience Corp. has completed a human clinical study comparing its oral DehydraTECH-liraglutide to injected Saxenda® liraglutide. The results indicate a significant reduction in adverse events for the oral formulation, suggesting potential for FDA registration. The study also demonstrated comparable safety and tolerability, positioning Lexaria to explore partnerships for an oral GLP-1 alternative.
Read more →LEXXLexaria Attending BIO International Convention
Lexaria Bioscience Corp. will attend the BIO International Convention in Boston from June 16-19, 2025. The company seeks to engage with potential partners and investors to further develop its DehydraTECH drug delivery platform. The convention is expected to facilitate numerous one-on-one meetings with industry leaders in various health sectors.
Read more →LEXXLexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Lexaria Bioscience Corp. has provided an update on its Material Transfer Agreement with PharmaCO, which involves evaluating its DehydraTECH technology in pre-clinical studies. Initial studies have been completed, and PharmaCO is interested in reviewing safety and efficacy data from Lexaria's ongoing human study in Australia. The collaboration is expected to continue, with potential for further human clinical studies.
Read more →LEXXLexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Lexaria Bioscience Corp. has completed a registered direct offering, raising $2 million by selling 2 million shares at $1.00 each. The offering was executed with a single institutional investor and aimed to support working capital and corporate purposes. CEO Richard Christopher expressed satisfaction with the funding achieved despite market difficulties.
Read more →LEXX▼ -20.1%on this news· ran to -31% by day 3shared move
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Lexaria Bioscience Corp. has announced a registered direct offering of 2 million shares of common stock at $1.00 per share, aiming to raise $2 million. The offering is set to close around April 28, 2025, pending customary conditions. Proceeds will support working capital and corporate initiatives.
Read more →LEXX▼ -20.1%on this news· ran to -31% by day 3shared move
Lexaria Announces $2 Million Registered Direct Offering of Common Stock Kelowna, British Columbia
Lexaria Bioscience Corp. announced a definitive agreement for a $2 million registered direct offering of common stock. The institutional investor will purchase 2,000,000 shares at a price of $1.00 per share, with the expected closing date set for April 28, 2025. Proceeds from this offering will be used for working capital and other general corporate purposes. The offering will be conducted under a shelf registration statement that has been declared effective by the SEC.
Read more →LEXX▲ +8.9%on this newsshared move
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Lexaria Bioscience Corp. is positioned to benefit from recent developments in the GLP-1 drug sector, particularly with its DehydraTECH technology, which aims to improve oral drug delivery and reduce side effects. Recent announcements from Pfizer and Eli Lilly highlight the challenges and opportunities in this space. While Eli Lilly's orfoglipron shows promise, Pfizer's setbacks underscore the difficulties in developing effective oral GLP-1 therapies. Lexaria's technology may play a crucial role in overcoming these hurdles.
Read more →LEXX▼ -8.4%on this news· ran to -20% by day 3
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Lexaria Bioscience Corp. has completed patient enrollment for its Phase 1b study GLP-1-H24-4, which investigates the safety and efficacy of DehydraTECH formulations in diabetes management. The study includes 24 patients in each of its five arms, focusing on oral delivery of drugs like semaglutide and cannabidiol. Results are expected in Q4 2025.
Read more →LEXXLexaria’s Human GLP-1 Study #5 Begins Dosing
Lexaria Bioscience Corp. has initiated dosing for its human study GLP-1-H25-5, which compares the efficacy of oral DehydraTECH-liraglutide against injected liraglutide. The study aims to evaluate pharmacokinetics and safety. Previous rodent studies indicated significant weight and blood sugar reductions with the oral formulation. Results will be disclosed upon completion.
Read more →LEXX▼ -5.2%on this news· ran to +21% by day 3
Lexaria’s DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound®
Lexaria Bioscience Corp. announced promising results from its study comparing DehydraTECH-tirzepatide oral capsules to Eli Lilly's injectable Zepbound. The oral capsules demonstrated consistent blood accumulation and a significant reduction in adverse events. Lexaria plans to expand its research based on these findings, indicating potential for a viable oral alternative to current injectable treatments.
Read more →LEXXThe Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Lexaria Bioscience is advancing its strategy in the GLP-1 drug market, focusing on its DehydraTECH technology to improve drug delivery. The recent FDA approval of semaglutide for chronic kidney disease highlights the potential of GLP-1 drugs. Despite challenges such as gastrointestinal side effects and injection aversion, the sector is expected to grow significantly.
Read more →LEXX▲ +5.5%on this newsshared move
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Lexaria Bioscience Corp. has secured ethics committee approval for the fifth arm of its Phase 1b study on DehydraTECH-tirzepatide. This approval allows dosing to commence in the study, which aims to evaluate the effectiveness of GLP-1 drugs. The company has previously received approvals for the first four arms and is making swift progress in patient recruitment.
Read more →LEXX▼ -10.1%on this newsshared move
Lexaria’s Strategic Business Pursuit of DehydraTECH-Liraglutide
Lexaria Bioscience Corp. has announced its strategic decision to explore commercial opportunities for an orally-dosed liraglutide using its DehydraTECH technology. The company has filed patent applications and plans to commence pilot clinical testing in humans. Positive results from these studies could lead to the world's first oral liraglutide, addressing a significant market need.
Read more →LEXX▼ -5.3%on this news
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Lexaria Bioscience Corp. has been granted two new patents for its DehydraTECH technology aimed at treating epilepsy. These patents expand the company's intellectual property portfolio and enhance its potential for commercial partnerships. The technology has shown effectiveness in reducing seizures in animal studies and is absorbed more efficiently than existing treatments.
Read more →LEXXLexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Lexaria Bioscience Corp. has initiated a biodistribution study for its DehydraTECH-semaglutide formulation. This study aims to track how the drug distributes in the body using fluorescent imaging in rodent models. The results may provide insights into the drug's efficacy and localization patterns, potentially enhancing future partnerships.
Read more →LEXXLexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Lexaria Bioscience Corp. has received independent ethics board approval for its first human pilot study, GLP-1-H25-5, to investigate DehydraTECH-liraglutide in an oral capsule format. This study aims to compare the oral formulation with the conventional injected liraglutide. Positive results from prior animal studies suggest potential benefits for weight loss and diabetes management. The study will involve 8-10 healthy volunteers to assess safety and pharmacokinetics.
Read more →LEXX▼ -6.3%on this newsshared move
Lexaria’s Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly’s Injectable GLP-1/GIP Drug Zepbound®
Lexaria Bioscience Corp. announced promising results from their study comparing oral DehydraTECH-tirzepatide with Eli Lilly's injected Zepbound. The oral formulation demonstrated a 47% reduction in adverse events and comparable efficacy in blood glucose control. Lexaria aims to further optimize this oral delivery method, which could significantly improve patient tolerability.
Read more →LEXXLexaria’s Registered GLP-1 Study #4 Begins Dosing
Lexaria Bioscience Corp. has initiated dosing in its Phase 1b study, GLP-1-H24-4, aimed at evaluating the safety and effectiveness of its DehydraTECH technology with GLP-1 drugs. The study will involve 20 participants across multiple arms, comparing DehydraTECH-processed drugs against established treatments. The company anticipates potential benefits in diabetes management and weight loss.
Read more →LEXXLexaria Forms New Scientific Advisory Board
Lexaria Bioscience Corp. has established a new Scientific Advisory Board (SAB) to enhance its drug delivery platform technology. The SAB, chaired by Lexaria's President and Chief Scientific Officer John Docherty, includes four experts with extensive experience in pharmaceutical development. This initiative aims to guide Lexaria's strategic plans and support the commercialization of its DehydraTECH technology.
Read more →LEXXEsteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Lexaria Bioscience Corp. has appointed Dr. Michael Gibson as its Chief Medical Advisor. Dr. Gibson, a renowned interventional cardiologist and researcher, will work closely with Lexaria's President to advance the company's DehydraTECH drug delivery technology. His extensive background in clinical trials and cardiovascular research is anticipated to significantly benefit Lexaria's initiatives, particularly in hypertension.
Read more →LEXXLiraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Lexaria Bioscience Corp. has announced the initiation of a human pilot study for DehydraTECH-liraglutide, following positive results from an animal study. The study aims to evaluate the safety and pharmacokinetics of this oral formulation against Saxenda® injectable liraglutide. If successful, it may lead to further investigations in Phase I trials.
Read more →LEXXRevolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Lexaria Bioscience Corp. highlights the expanding therapeutic benefits of GLP-1 drugs, including semaglutide, which are being investigated for conditions like heart disease, Alzheimer's, and liver disease. The market for these drugs is projected to generate over $100 billion annually, driven by their efficacy and safety. Lexaria's DehydraTECH technology aims to improve drug delivery, potentially enhancing the impact of GLP-1 therapies.
Read more →LEXXLexaria’s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Lexaria Bioscience Corp. has completed dosing for its third human pilot study of DehydraTECH-processed tirzepatide, an oral formulation of the GLP-1 receptor agonist. The study involved nine healthy volunteers and showed no serious adverse events. Results are expected to be analyzed in December, with findings available in January 2025.
Read more →LEXXALL Study Groups using DehydraTECH Processing Outperform Rybelsus® in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Lexaria Bioscience Corp. announced positive results from its 12-week diabetes animal study, WEIGHT-A24-1, where all groups using DehydraTECH technology outperformed the Rybelsus® control group in body weight and blood sugar control. The top performers, DehydraTECH-liraglutide and DehydraTECH-CBD, showed significant improvements, supporting the company's plans for a Phase 1b human study in Australia. The study's design aimed to maintain a diabetic state, providing insights into the efficacy of various formulations.
Read more →LEXX▼ -6.2%on this news
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Lexaria Bioscience Corp. has contracted a research organization to conduct the first-ever biodistribution study of DehydraTECH-semaglutide. This study aims to evaluate how the DehydraTECH processing may enhance the drug's distribution compared to conventional methods. Results are expected by May 2025, which could improve collaborations with industry partners.
Read more →LEXXEthics Board Approval Granted for Lexaria’s 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Lexaria Bioscience Corp. has received ethics board approval for its Phase 1b study on DehydraTECH technology aimed at treating diabetes and weight loss. The study will involve multiple formulations, including DehydraTECH-CBD and semaglutide. Manufacturing for the study has been completed, and the company anticipates starting dosing by late December 2024 or January 2025. The study aims to evaluate safety and efficacy compared to existing treatments.
Read more →LEXX▲ +5.9%on this news
Lexaria Updates Fast-Moving GLP-1 ‘Arm’s Race’ Developments
Lexaria Bioscience Corp. is enhancing its DehydraTECH platform for GLP-1 drugs amid a competitive landscape dominated by major players like Novo Nordisk and Eli Lilly. The GLP-1 sector is witnessing a surge in mergers and acquisitions, with projections indicating revenues could reach between $100 billion to $471 billion annually. Lexaria aims to position its technology as essential for pharmaceutical companies developing next-generation GLP-1 drugs.
Read more →LEXXPositive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Lexaria Bioscience Corp. announced positive results from its 12-week animal study, WEIGHT-A24-1, focusing on blood sugar levels. The DehydraTECH-liraglutide and certain DehydraTECH-CBD formulations outperformed traditional GLP-1 drugs, indicating potential for improved oral drug delivery. Additional data, including body weight and pharmacokinetic results, are pending.
Read more →LEXXPositive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Lexaria Bioscience Corp. announced positive partial results from its 12-week animal study on weight loss using DehydraTECH-liraglutide and select DehydraTECH-CBD formulations. The study demonstrated that these formulations outperformed traditional GLP-1 drugs like Rybelsus and semaglutide. Accelerated weight loss was particularly noted in the final four weeks of the study, indicating potential for further research.
Read more →LEXXLexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Lexaria Bioscience Corp. has successfully closed a registered direct offering, raising approximately $5 million by selling 1,633,987 shares at $3.06 each. The company will use the proceeds for working capital and corporate purposes. Additionally, unregistered warrants for 4,551,019 shares were issued, which will be exercisable upon stockholder approval. Certain outstanding warrants will also be cancelled following the offering.
Read more →LEXX▼ -6.2%on this newsshared move
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Lexaria Bioscience Corp. has announced a registered direct offering of 1,633,987 shares at $3.06 each, aiming to raise approximately $5 million. The offering will include unregistered warrants for additional shares. The proceeds are intended for working capital and corporate purposes, with the closing expected around October 16, 2024, pending customary conditions.
Read more →LEXX▼ -6.2%on this newsshared move
KELOWNA, BC / ACCESSWIRE /
Lexaria Bioscience Corp. announced a definitive agreement for a registered direct offering of 1,633,987 shares of common stock, priced at $3.06 each, expected to generate approximately $5 million in gross proceeds. Concurrently, the company will issue unregistered warrants to purchase additional shares at the same exercise price. The funds raised will be utilized for working capital and general corporate purposes. The offering is contingent on customary closing conditions and stockholder approvals, expected to close around October 16, 2024.
Read more →LEXXLexaria’s GLP-1 Human Pilot Study #3 Begins Dosing
Lexaria Bioscience Corp. has initiated dosing in its third human pilot study for DehydraTECH-processed tirzepatide, a GLP-1 and GIP dual-action drug. The study will assess tolerability, pharmacokinetics, and blood sugar control in up to 10 healthy volunteers. Initial dosing is expected to conclude on October 13, with a second phase planned for mid-November. No serious adverse events have been reported so far.
Read more →LEXXLexaria Updates Current GLP-1 Market
Lexaria Bioscience Corp. has provided an update on the rapidly growing GLP-1 receptor agonist market, highlighting significant revenue increases from leading drugs. The company anticipates that its DehydraTECH delivery system will play a crucial role in the future of oral GLP-1 drug delivery. Additionally, the potential for expanded therapeutic applications for GLP-1 drugs is promising, particularly in cardiovascular health.
Read more →LEXXLexaria Appoints Michael Shankman as Chief Financial Officer
Lexaria Bioscience Corp. has appointed Michael Shankman as its new Chief Financial Officer, effective immediately. Shankman, a CPA with extensive experience in financial operations, has previously worked with the company and is expected to contribute significantly to its growth. CEO Richard Christopher expressed enthusiasm for Shankman's appointment, highlighting the company's potential for advancements in pharmaceutical research.
Read more →LEXXLexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Lexaria Bioscience Corp. has received approval from an independent review board to initiate human pilot study #3, which will evaluate a DehydraTECH-processed version of tirzepatide in an oral format. The study aims to compare the pharmacokinetics and tolerability of the oral dose against an injected dose. Recruitment for the study is set to begin shortly, with dosing expected to start in late October.
Read more →LEXXLexaria Releases Strategic Letter from the Outgoing CEO
Lexaria Bioscience Corp. has announced a strategic update from outgoing CEO Chris Bunka, highlighting the company's successful pivot to pharmaceutical studies and its recent financial achievements. The company has raised significant funds and is preparing to launch Phase 1b studies in hypertension and diabetes. New CEO Richard Christopher is expected to lead the company into a promising future with a focus on execution and commercial opportunities.
Read more →LEXXLexaria Welcomes Industry Veteran as New CEO
Lexaria Bioscience Corp. has appointed Richard Christopher as the new CEO, effective August 31, 2024, succeeding Chris Bunka, who will remain as Chairman and Executive Strategic Advisor. Christopher, with extensive experience in the pharmaceutical sector, aims to lead Lexaria into a new era focused on drug delivery advancements. The company is preparing for significant growth and ongoing research in the GLP-1 marketplace.
Read more →LEXXLexaria Releases Strategic Letter from the Outgoing CEO Kelowna, British Columbia
Lexaria Bioscience Corp. announced the strategic update from its outgoing CEO Chris Bunka. The company has shifted its focus towards executing its pharmaceutical strategies, particularly in cardiometabolic and GLP-1 sectors. Notably, Lexaria has filed for an IND with the FDA and is preparing for two Phase 1 studies in 2025. The company has enjoyed financial growth and considerable interest from the pharmaceutical industry, marking a significant evolution in its operations.
Read more →LEXX▼ -6.6%on this news· ran to -20% by day 3shared move
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Lexaria Bioscience Corp. has signed a Material Transfer Agreement with a pharmaceutical company to assess its DehydraTECH technology in pre-clinical studies. Lexaria will provide specific formulations for evaluation, with results expected in about six months. This agreement highlights the potential of DehydraTECH in enhancing drug delivery and bio-absorption.
Read more →LEXX▲ +10.6%on this news· ran to +34% by day 1shared move
Lexaria’s Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus® Oral Capsules
Lexaria Bioscience Corp. announced positive results from its second human pilot study of DehydraTECH-processed Rybelsus capsules, demonstrating zero adverse events among participants. The study indicated improved tolerability and absorption compared to traditional Rybelsus tablets. While some mild adverse events were reported with the tablets, the findings suggest potential for enhanced oral GLP-1 drug delivery.
Read more →LEXXFirst Results from Lexaria’s Second GLP-1 Human Pilot Study
Lexaria Bioscience Corp. has announced the first results from its second GLP-1 human pilot study, which indicate that DehydraTECH-processed Rybelsus shows a trend toward improved absorption compared to unprocessed Rybelsus. The study revealed an average increase of 18.8% in semaglutide levels under fed conditions, although the results were not statistically significant. Lexaria plans to continue its GLP-1 experimental program with further studies.
Read more →LEXX▼ -7.9%on this newsshared move
Positive 8-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Lexaria Bioscience Corp. has reported positive results from its 8-week animal study on DehydraTECH-liraglutide, which outperformed DehydraTECH-semaglutide in promoting weight loss. The study, which involves diabetic Zucker rats, aims to evaluate the effectiveness of oral delivery of GLP-1 drugs. Further results are expected as the study continues.
Read more →LEXXPositive Interim Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Lexaria Bioscience Corp. announced positive interim results from its animal study WEIGHT-A24-1, showing that DehydraTECH-liraglutide outperformed DehydraTECH-semaglutide in reducing blood sugar levels. The study also indicated that certain DehydraTECH-CBD formulations could enhance diabetes control when used with GLP-1 drugs. Further results are anticipated as the study continues.
Read more →LEXXPositive Results from Lexaria’s Molecular Characterization Study
Lexaria Bioscience Corp. announced positive results from its study on DehydraTECH processed semaglutide, demonstrating efficient release in simulated gastric conditions. The findings suggest that Lexaria's technology can achieve the desired monomeric form without proprietary ingredients like SNAC, indicating potential for better oral delivery of GLP-1 drugs. Further research is planned to explore additional parameters.
Read more →LEXXPositive Interim Body Weight Results from Lexaria’s Diabetes Animal Study
Lexaria Bioscience Corp. has reported positive interim results from its diabetes animal study, WEIGHT-A24-1, showing significant weight loss in subjects treated with DehydraTECH-processed drugs. The study indicates that both DehydraTECH-CBD and DehydraTECH-liraglutide formulations have led to weight loss. Dosing in the final study arms has commenced, with further results expected in the coming weeks.
Read more →LEXXPositive Interim Body Weight Results from Lexaria's Diabetes Animal Study DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC t
Lexaria Bioscience Corp. announced promising interim results from its diabetes animal study, WEIGHT-A24-1, which utilize its DehydraTECH technology. The study revealed significant reductions in body weight gain in animals treated with DehydraTECH-processed liraglutide and semaglutide. With further dosing scheduled for analysis, the study aims to optimize drug delivery formulations and evaluate their effectiveness in managing diabetes. Ongoing data processing will provide insights into blood glucose control and potential absorption advantages.
Read more →LEXXLexaria Preparing For Strategic Growth
Lexaria Bioscience Corp. is executing a strategic growth plan that includes expanding its management team and initiating new R&D projects related to GLP-1 molecules. The company has received FDA clearance for its Phase 1b hypertension study, which it aims to launch soon. CEO Chris Bunka expressed confidence in the company's medium- and long-term strategies.
Read more →LEXXDosing is Complete in Lexaria’s Second GLP-1 Human Pilot Study
Lexaria Bioscience Corp. has completed all dosing in its second GLP-1 human pilot study, which investigates the absorption of semaglutide through innovative delivery methods. The study compares a positive control with new formulations, including an in-mouth dissolvable tablet. Results are expected to validate earlier findings and will be analyzed in the coming months.
Read more →LEXX▼ -5.5%on this newsshared move
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Lexaria Bioscience Corp. has announced the granting of three new patents, enhancing its portfolio to 46 patents worldwide. The patents cover transdermal delivery of lipophilic agents, antiviral agent delivery methods, and treatments for epilepsy. Notably, the DehydraTECH technology has demonstrated improved bio-absorption rates for various drugs, which could have significant implications for future treatments.
Read more →LEXXLexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Lexaria Bioscience Corp. has contracted a CRO to conduct a 12-week chronic study on DehydraTECH-GLP-1 formulations, focusing on weight loss and blood sugar reduction. This study, the most extensive of its kind for Lexaria, will involve multiple treatment arms and is expected to provide significant insights into the safety and efficacy of its formulations. The study will be conducted in Australia and aims for FDA recognition as a Phase 1b registrational study.
Read more →LEXXDosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
Lexaria Bioscience Corp. has completed the second dosing arm of its GLP-1 human pilot study, GLP-1-H24-2, involving nine participants. This study compares different formulations of semaglutide, including a novel dissolvable tablet. The final dosing arm is expected to conclude in early July, focusing on the absorption of semaglutide through sublingual tissues.
Read more →LEXXLexaria Awards Contract For Third GLP-1 Human Pilot Study
Lexaria Bioscience Corp. has contracted a research organization to conduct its third human pilot study on a new oral formulation of tirzepatide, utilizing its DehydraTECH technology. The study aims to compare the oral version with the currently available injectable form, focusing on absorption, tolerability, and pharmacokinetics. Results could significantly impact the delivery of GLP-1 medications.
Read more →LEXXLexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
Lexaria Bioscience Corp. has been awarded two new patents for its DehydraTECH technology, focusing on treating hypertension and epilepsy. The hypertension patent is the third in its category, while the epilepsy patent complements previous findings on CBD's effectiveness. These patents bolster Lexaria's growing portfolio, now totaling 43 patents worldwide.
Read more →LEXXDosing Begins in Lexaria’s Comprehensive GLP-1 Animal Study
Lexaria Bioscience Corp. has commenced dosing in its 12-week animal study, WEIGHT-A24-1, to assess the effects of DehydraTECH-processed GLP-1 drugs on diabetes treatment and weight loss. The study will compare pure semaglutide and liraglutide with reformulated versions and evaluate their effectiveness in reaching brain tissue and improving health outcomes. Over 1,500 blood plasma samples will be analyzed to gather pharmacokinetic data.
Read more →LEXXLexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
Lexaria Bioscience Corp. has commenced its second GLP-1 human pilot study, GLP-1-H24-2, with all nine participants having completed their first dosing visit. The study will evaluate three formulations of semaglutide, including a novel dissolvable oral tablet. This research aims to enhance drug absorption and minimize side effects compared to traditional swallowed formulations.
Read more →LEXX▲ +8.9%on this newsshared move
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
Lexaria Bioscience Corp. has announced a new research program in collaboration with the National Research Council of Canada to evaluate the molecular characteristics of DehydraTECH processed with the GLP-1 drug, semaglutide. The program aims to enhance the understanding of its mode of action and performance, potentially leading to improved drug formulations. Initial studies have shown promising results in terms of absorption and reduced adverse effects.
Read more →LEXXLexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
Lexaria Bioscience Corp. has entered a warrant exercise agreement, resulting in approximately $4.7 million in gross proceeds. The company exercised 2,917,032 warrants, with a new exercise price of $4.75 per share for newly issued warrants. The funds are intended for working capital and corporate purposes, extending operational capabilities into 2025.
Read more →LEXX▲ +16.1%on this news
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Lexaria Bioscience Corp. has received ethics approval for its second human pilot study investigating GLP-1 drugs using its DehydraTECH technology. The study will involve up to nine healthy volunteers and compare a standard semaglutide formulation with two DehydraTECH-enabled versions. Recruitment starts immediately, with dosing expected within 30 days. The study aims to enhance drug delivery and reduce side effects.
Read more →LEXXLexaria Awarded New Patents
Lexaria Bioscience Corp. has been granted two new patents in the USA for compositions and methods to treat epilepsy, enhancing its innovative drug delivery platform. Additionally, a patent for improved delivery of antiviral agents has been awarded in Japan. These patents bolster Lexaria's intellectual property portfolio, which now includes 41 patents globally.
Read more →LEXX▼ -12.5%on this news
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Lexaria Bioscience Corp. has appointed Nelson Cabatuan as Chief Financial Officer, effective immediately. Cabatuan, who has over 15 years of experience in corporate finance within the life sciences sector, will lead the company's financial operations. His expertise is expected to support Lexaria's growth strategy, particularly in maximizing the potential of its DehydraTECH platform.
Read more →LEXX▲ +11.6%on this news· ran to +23% by day 1
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Lexaria Bioscience Corp. has contracted a research organization to conduct its second human pilot study of a DehydraTECH-powered GLP-1 formulation. This study will compare a new dissolvable oral tablet with existing formulations, aiming to improve drug absorption and delivery. If successful, it could lead to a significant advancement in GLP-1 therapies.
Read more →LEXX▲ +12.7%on this news· ran to +83% by day 3shared move
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Lexaria Bioscience Corp. has announced the commencement of an 8-week animal study, WEIGHT-A24-1, to investigate the effects of DehydraTECH-processed GLP-1 drugs and cannabidiol on diabetes and weight loss. The study will analyze various formulations and their impact on blood glucose levels and weight loss over a 12-week period. The research aims to assess the efficacy of enhanced brain absorption delivery methods.
Read more →LEXX7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
Lexaria Bioscience Corp. announced positive results from an 8-week animal study showing a 7% weight loss and significant blood glucose reduction using its DehydraTECH-CBD formulation. The company is set to begin a new animal study, WEIGHT-A24-1, to further explore weight loss and blood glucose control with DehydraTECH formulations. Recent human studies also indicate improved absorption of semaglutide processed with DehydraTECH.
Read more →LEXX▼ -15.4%on this news· ran to +30% by day 3shared move
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Lexaria Bioscience Corp. has received FDA clearance for its Phase 1b hypertension clinical trial, HYPER-H23-1, utilizing DehydraTECH-CBD. This marks a significant achievement for the company, demonstrating that its technology meets FDA standards for clinical testing. The trial aims to evaluate the safety and efficacy of DehydraTECH-CBD in hypertensive patients, building on previous positive clinical data.
Read more →LEXX▼ -6.5%on this news
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Lexaria Bioscience Corp. has completed a registered direct offering, raising approximately $3.6 million by selling 1,558,443 shares at $2.31 each. The funds will be utilized for research and development, as well as legal costs. The offering was facilitated by H.C. Wainwright & Co., and the company holds a significant patent portfolio.
Read more →LEXX▼ -9.2%on this newsshared move
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Lexaria Bioscience Corp. has announced a registered direct offering of 1,558,443 shares priced at $2.31 each, aiming to raise approximately $3.6 million. The proceeds will be allocated to research and development as well as general working capital. The offering is expected to close around February 16, 2024, pending customary conditions.
Read more →LEXX▼ -9.2%on this newsshared move
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Kelowna, British Columbia
Lexaria Bioscience Corp. has announced a registered direct offering of 1,558,443 shares of common stock priced at $2.31 per share, aiming to raise approximately $3.6 million. The company plans to use the net proceeds for research and development, as well as general working capital. The offering is set to close around February 16, 2024, pending the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering.
Read more →LEXXCEO LETTER TO STAKEHOLDERS According to the Wall Street Journal, near the end of 2023, there were 446 companies listed on the Nasdaq that were trading under $1 and risking being de-listed; compared to nearly nil in 2021.
In a recent letter to stakeholders, Lexaria's CEO addressed the challenges faced by the company and the broader microcap sector in 2023, including difficulties in capital markets and stock price declines. Despite these obstacles, Lexaria achieved notable advancements, including signing a new corporate client and boosting its stock price above the $1 minimum required by Nasdaq. The company also reported a significant increase in institutional interest. Looking ahead, Lexaria is committed to pursuing innovation in its research and development efforts, particularly in collaborations focused on its DehydraTECH technology.
Read more →LEXXLexaria Unveils Extensive Planned 2024 GLP-1 Study Program
Lexaria Bioscience Corp. has announced an extensive research program for 2024 to evaluate its DehydraTECH technology for improved delivery of GLP-1 drugs. The program includes multiple studies targeting drugs like semaglutide and tirzepatide, focusing on pharmacokinetics and tolerability. Initial pilot studies have shown promising results, prompting further investigation to support commercial partnerships.
Read more →LEXX▲ +5.6%on this newsshared move
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
Lexaria Bioscience Corp. has announced its proprietary DehydraTECH platform, which improves the delivery of active pharmaceutical ingredients into the bloodstream. This technology has shown enhanced bioabsorption for various drugs, including cannabinoids and antiviral medications. The potential applications for GLP-1 drugs are expanding, with implications for treating numerous health conditions. Lexaria holds a strong intellectual property portfolio with 37 patents granted.
Read more →LEXXLexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
Lexaria Bioscience Corp. has announced advancements in its proprietary DehydraTECH(TM) drug-delivery platform, which aims to enhance the delivery and efficacy of GLP-1 agonists. These drugs, known for their role in treating type 2 diabetes, are being explored for various other therapeutic uses, including Alzheimer's and heart disease. The company's technology has demonstrated improved bio-absorption for several active pharmaceutical ingredients.
Read more →LEXX▲ +6.9%on this newsshared move
Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide
Lexaria Bioscience Corp. announced positive results from a pilot study evaluating its DehydraTECH technology for the oral delivery of semaglutide, the active ingredient in Rybelsus. The study demonstrated that DehydraTECH GLP-1 achieved higher blood levels of semaglutide, better blood glucose control, and reduced side effects compared to the standard Rybelsus tablets. Lexaria plans to conduct further studies to explore the effectiveness of DehydraTECH with GLP-1 drugs.
Read more →LEXX▲ +6.9%on this newsshared move
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus -Branded GLP-1 drug Semaglutide Final results from a human pilot study show DehydraTECH TM -powered semaglutide outperforms Rybelsus : Sustained
Lexaria Bioscience Corp. reported positive results from a human pilot study evaluating its DehydraTECH technology for enhancing the oral delivery of semaglutide, the active ingredient in Rybelsus. The study found that the DehydraTECH formulation produced significantly higher blood levels of semaglutide, demonstrating more effective glucose control compared to the original Rybelsus tablet. Additionally, the DehydraTECH formulation resulted in fewer side effects than Rybelsus. Following these promising results, Lexaria is preparing for further studies to explore the technology's potential in GLP-1 drug delivery.
Read more →LEXXLexaria’s Investigational New Drug Application Filing Update
Lexaria Bioscience Corp. is preparing to submit an Investigational New Drug application for its Phase 1b Hypertension Clinical Trial within 45 days. The submission was delayed due to documentation issues with a supplier, which have now been resolved. Lexaria's previous studies indicate that its DehydraTECH-CBD formulation has the potential for significant clinical benefits in reducing blood pressure without serious adverse events.
Read more →LEXXLexaria’s Technology Lowers Blood Glucose More Effectively than Rybelsus®-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
Lexaria Bioscience Corp. announced positive interim results from a human pilot study evaluating its DehydraTECH technology combined with semaglutide, the active ingredient in Rybelsus. The study demonstrated significantly lower blood glucose levels in participants using DehydraTECH compared to those using Rybelsus alone. This marks a notable advancement in the oral delivery of GLP-1 drugs, with further studies planned to explore the technology's potential.
Read more →LEXX▲ +24.4%on this newsshared move
Lexaria’s Technology Improves the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide in Human Pilot Study
Lexaria Bioscience Corp. announced positive interim results from a human pilot study evaluating its DehydraTECH technology for the oral delivery of semaglutide, the active ingredient in Rybelsus. The study demonstrated that DehydraTECH-enhanced semaglutide achieved higher blood levels and faster peak delivery while reducing side effects compared to the standard formulation. Further results, including blood glucose data, are expected soon.
Read more →LEXX▲ +5.1%on this news
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
Lexaria Bioscience Corp. is expanding its studies on its DehydraTECH platform, focusing on GLP-1 drugs for diabetes treatment. The global diabetes drug market is expected to grow from $63.1 billion in 2021 to $82.93 billion by 2027. Lexaria's early studies have shown positive effects on glucose levels and body weight, prompting further research.
Read more →LEXXLexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Lexaria Bioscience Corp. is exploring its DehydraTECH drug-delivery platform to enhance the effectiveness of GLP-1 drugs, which are used for managing diabetes and obesity. The company plans to conduct new studies following promising early results that showed reduced blood sugar levels and weight loss. This initiative aligns with the growing demand for more effective diabetes treatments.
Read more →LEXX▼ -6.6%on this news
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Lexaria Bioscience Corp. has entered a global exclusive collaboration with SulfoSyn Limited for the use of its DehydraTECH technology in non-pharmaceutical applications of sulforaphane. The agreement includes upfront payments, ongoing royalties, and manufacturing operations to be conducted by Lexaria. This partnership aims to leverage the superior qualities of sulforaphane for commercial use.
Read more →LEXX▼ -6.6%on this newsshared move
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded Minimum ongoing payments, roya
Lexaria Bioscience Corp. has entered into a global exclusive collaboration with SulfoSyn Limited for the use of its DehydraTECH technology, specifically for non-pharmaceutical applications of sulforaphane. This agreement includes an upfront cash payment, minimum ongoing payments, and future royalties based on exceeding those minimums. Furthermore, Lexaria will conduct specific manufacturing operations at a U.S. partner facility for an initial two-year term. The collaboration builds on prior exploratory work on the advantageous qualities of sulforaphane, known for its various health benefits.
Read more →LEXXLexaria Granted Two New Patents in Canada
Lexaria Bioscience Corp. has been granted two new patents in Canada, bringing its total to 37 worldwide. The patents cover innovations in drug delivery, specifically for lipophilic active agents and infused tobacco leaves. These advancements may aid in treating nicotine addiction and enhance the effectiveness of their DehydraTECH technology.
Read more →LEXXLexaria Granted Two New Patents in Canada Lexaria now holds 37 granted patents world-wide Potential application in treating nicotine addiction Kelowna, British Columbia
Lexaria Bioscience Corp. has recently been granted two new patents by the Canadian Intellectual Property Office, bringing its total to 37 patents globally. The patents include innovations for stable beverage compositions and the infusion of active agents in tobacco leaves, with the latter aimed at potential nicotine addiction treatments. Lexaria is also seeking international patent protection for its oral-nicotine technology, further emphasizing its commitment to drug delivery advancements. This development signals growth in Lexaria's intellectual property and enhanced potential for its DehydraTECH technology.
Read more →LEXXLexaria Announces Pricing of $1.6 Million Registered Direct Offering
Lexaria Bioscience Corp. has announced a registered direct offering to raise approximately $1.6 million by selling shares and warrants to a healthcare-focused institutional investor. The offering is expected to close around October 3, 2023, pending customary closing conditions. This funding will support Lexaria's ongoing research and development efforts.
Read more →LEXXLexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Lexaria Bioscience Corp. plans to evaluate the impact of its DehydraTECH technology on GLP-1 drugs, including Ozempic, Wegovy, and Rybelsus. The studies aim to enhance oral bioavailability, reduce side effects, and improve cost-effectiveness. Initial research will begin soon, expanding Lexaria's diabetes study program. The potential market for GLP-1 drugs is estimated to reach $100 billion by 2030.
Read more →LEXXLexaria Provides Update on Investigational New Drug Application Progress
Lexaria Bioscience Corp. has provided an update on its Investigational New Drug application for the Phase 1b Hypertension Clinical Trial, HYPER-H23-1. While the company has completed batch manufacturing and documentation preparation, delays from a material supplier have postponed the IND submission to the FDA. Lexaria aims to file the IND as soon as the outstanding information is received.
Read more →LEXX▲ +6.8%on this news
Lexaria’s DehydraTECH-Nicotine Faster than ZYN and on!
Lexaria Bioscience Corp. has announced that its DehydraTECH-Nicotine pouch reaches maximum nicotine levels in the bloodstream faster than competitors ZYN and on!. The human study NIC-H22-1 showed that DehydraTECH-Nicotine is 15% faster than on! and 20% faster than ZYN. Users reported more pleasurable effects and fewer negative side effects compared to the competitors.
Read more →LEXXLexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
Lexaria Bioscience Corp. plans to conduct a human clinical study on DehydraTECH-CBD aimed at diabetes control and weight loss. This decision follows promising pre-clinical results showing significant reductions in blood glucose and body weight in obese diabetic animals. The study will be conducted at a medical research hospital in Europe, with further details to be released.
Read more →LEXXLexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
Lexaria Bioscience Corp. has launched a new subsidiary, Lexaria Nutraceutical Corp., to leverage its DehydraTECH Technology for consumer packaged goods. The subsidiary is restricted from producing pharmaceutical products. Additionally, Lexaria is nearing the release of results from its human nicotine study, NIC-H22-1, which has completed dosing. The oral nicotine pouch market is expected to grow substantially in the coming years.
Read more →LEXXLexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study Kelowna, British Columbia
Lexaria Bioscience Corp. has established a new subsidiary, Lexaria Nutraceutical Corp., to leverage its patented DehydraTECH Technology for consumer packaged goods. This subsidiary will focus on non-nicotine and non-cannabis products, while Lexaria Pharmaceutical Corp. retains rights to manufacture pharmaceutical products involving other molecules. Additionally, Lexaria has completed dosing for its NIC-H22-1 human nicotine study and is expected to release results soon, amidst a growing oral nicotine market projected to reach $21.84 billion by 2027.
Read more →LEXXLexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Lexaria Bioscience Corp. has been granted a new U.S. patent for its DehydraTECH-nicotine technology, which enhances the delivery of nicotine through oral pouches. This patent recognizes the effectiveness of Lexaria's sublingual delivery method, which has demonstrated superior absorption rates in animal studies. The oral nicotine pouch market is expanding rapidly, driven by reduced health risks compared to traditional smoking.
Read more →LEXXLexaria Bioscience Announces Pricing of $2.0 Million Public Offering KELOWNA, BC / ACCESSWIRE / MAY 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug
Lexaria Bioscience Corp. has announced a public offering of 2,106,000 units at a price of $0.95 each, expecting to raise gross proceeds of approximately $2.0 million. The offering includes a share of common stock and a warrant for additional shares, both available immediately upon issuance. Maxim Group LLC is acting as the sole placement agent for the offering, which is anticipated to close on May 11, 2023, pending customary closing conditions.
Read more →LEXXLexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels Kelowna, British Columbia
Lexaria Bioscience Corp. announced positive results from its animal study DIAB-A22-1 on the effects of its DehydraTECH-CBD formulation in obese diabetic rats. The study demonstrated significant weight loss, improved triglyceride and cholesterol levels, particularly with lower dosing. While the treatment was well tolerated overall, potential sedative effects at higher doses were observed, affecting locomotor activity. The findings support further exploration of DehydraTECH-CBD's benefits in managing diabetes-related health issues.
Read more →LEXXCEO LETTER TO STAKEHOLDERS As 2022 came to a close, it isn't news that nearly all companies - not to mention most people - are facing challenges not experienced in years. Lexaria continues to navigate well and is focused
As 2022 closed, Lexaria continues to navigate challenges in the biotech landscape, focusing on their applied R&D efforts. Despite the economic downturn affecting numerous companies, Lexaria has managed to maintain staff levels and fiscal discipline. The company is currently in discussions with multiple large firms regarding the potential use of its DehydraTECH technology, signaling a proactive approach to partnerships. However, the company's stock price struggled in 2022, reflecting broader market trends and investor sentiment challenges.
Read more →LEXX▲ +5.8%on this news
Lexaria's Human Clinical Hypertension Study a Success HYPER-H21-4 using DehydraTECH-CBD evidenced: Exceptional safety and tolerability Statistically significant lowering of 24-hour ambulatory blood pressure ("BP") BP low
lxrp_ex991.htm EXHIBIT 99.1 Lexaria's Human Clinical Hypertension Study a Success HYPER-H21-4 using DehydraTECH-CBD evidenced: Exceptional safety and tolerability Statistically significant lowering of 24-hour ambulatory blood pressure ("BP") BP lowered for the entire 5-
Read more →LEXXLexaria Provides Annual Letter From the CEO Kelowna, British Columbia
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Provides Annual Letter From the CEO Kelowna, British Columbia - January 27, 2022 - Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an a
Read more →LEXX▲ +11.4%on this news
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with
lxrp_ex991.htm EXHIBIT 99.1 Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD rela
Read more →LEXXLexaria's DehydraTECH-CBD Lowers Blood Pressure Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability Kelowna, British Columbia
lxrp_ex991.htm EXHIBIT 99.1 Lexaria's DehydraTECH-CBD Lowers Blood Pressure Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability Kelowna, British Columbia - July 29, 2021 - Lexaria Bioscience Co
Read more →LEXXLexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs DehydraTECH improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 Kelo
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs DehydraTECH improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 Kelowna, British Columbia - June
Read more →LEXXLexaria's DehydraTECH TM -Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus Kelowna, British Columbia
lxrp_ex991.htm EXHIBIT 99.1 Lexaria's DehydraTECHTM-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus Kelowna, British Columbia, June 3, 2021 - Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the "Company" or "Lexaria"), a glo
Read more →LEXXLexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* Kelowna, British Columbia
PRESS RELEASE DATED MAY 6, 2021 lxrp_ex991.htm EXHIBIT 99.1 Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* Kelowna, British Columbia, May 6, 2021 - L
Read more →LEXXLexaria Appoints New Chief Financial Officer And Issues Consultant Warrants Kelowna, British Columbia
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Appoints New Chief Financial Officer And Issues Consultant Warrants Kelowna, British Columbia, April 15, 2021 - Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the "Company" or "Lexaria"), a global innovator in drug deliv
Read more →LEXXLexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Tuesday
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Tuesday, January 12, 2021 7:00 AM Topic: Exchange Listing Upgrade KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Biosci
Read more →LEXXLexaria Bioscience Corp. OTCQX:LXRP | LXX:CSE Drug Delivery Platform Innovator Investor Presentation December 2020 LexariaBioscience.com Focused on commercialization through partnerships and licensing Lexaria Bioscience
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Bioscience Corp. OTCQX:LXRP | LXX:CSE Drug Delivery Platform Innovator Investor Presentation December 2020 LexariaBioscience.com Focused on commercialization through partnerships and licensing Lexaria Bioscience - Corporate Highlights Disrupt
Read more →LEXXLexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH Remdesivir is one of several drugs to be evaluated Kelowna, British Columbia
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH Remdesivir is one of several drugs to be evaluated Kelowna, British Columbia, December 22, 2020 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "L
Read more →LEXXLexaria's Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs Demonstrates Improved Delivery of Two Classes of Drugs in Use Against HIV/AIDS and under investigation Against SARS-CoV-2/COVID-19 Kel
lxrp_ex991.htm EXHIBIT 99.1 Lexaria's Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs Demonstrates Improved Delivery of Two Classes of Drugs in Use Against HIV/AIDS and under investigation Against SARS-CoV-2/COVID-19 Kelowna, British Columbia, Decem
Read more →LEXXLexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M Asset Sale in Preparation for US National Securities Exchange Listing Kelowna, British Columbia
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85M Asset Sale in Preparation for US National Securities Exchange Listing Kelowna, British Columbia- November 19, 2020 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the
Read more →LEXXLexaria Bioscience Advances 2021 Strategic Initiatives Lexaria Focusing on Four Core Business Segments: Heart disease including hypertension Reduced-risk non combusted nicotine Improved antiviral drug delivery CBD from h
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Bioscience Advances 2021 Strategic Initiatives Lexaria Focusing on Four Core Business Segments: Heart disease including hypertension Reduced-risk non combusted nicotine Improved antiviral drug delivery CBD from hemp Kelowna, Britis
Read more →LEXXAltria and Lexaria Conclude Phase I Research and Development Program R&D Program Utilized Lexaria's Patented DehydraTECH TM Technology for Oral Nicotine Delivery Conclusion of Phase I allows for additional phased private
lxrp_ex991.htm EXHIBIT 99.1 Altria and Lexaria Conclude Phase I Research and Development Program R&D Program Utilized Lexaria's Patented DehydraTECHTM Technology for Oral Nicotine Delivery Conclusion of Phase I allows for additional phased private financings up to a further US
Read more →LEXXLexaria Bioscience Engages Investor Relations and Capital Markets Advisory Firm for its Shareholder Communications Program KELOWNA, BC /
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Bioscience Engages Investor Relations and Capital Markets Advisory Firm for its Shareholder Communications Program KELOWNA, BC / June 29, 2020 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a global innovato
Read more →LEXXLexaria Bioscience Announces Over US$2,000,000 Private Placement KELOWNA, BC / ACCESSWIRE /
lxrp_ex991.htm EXHIBIT 99.1 Lexaria Bioscience Announces Over US$2,000,000 Private Placement KELOWNA, BC / ACCESSWIRE / May 4, 2020 / Lexaria Bioscience Corp. (OTCQX: LXRP)(CSE: LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced th
Read more →LEXXLexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program Kelowna, British Columbia
Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program Kelowna, British Columbia- March 19, 2020 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, announces it is commencing a program,
Read more →LEXXLexaria Provides Update on Two Licensed Clients Kelowna, British Columbia
Lexaria Provides Update on Two Licensed Clients Kelowna, British Columbia- March 4, 2020 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has successfully processed its first Dehyd
Read more →LEXXLexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category Kelowna, British Columbia
Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category Kelowna, British Columbia- January 14, 2020 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a global innovator in dr
Read more →LEXXLexaria Bioscience CEO Discusses Strategic Outlook Lexaria Bioscience Corp ("Lexaria", or the "Company") is a global biotech leader in developing and implementing advanced technologies to better deliver Active Pharmaceut
Lexaria Bioscience CEO Discusses Strategic Outlook Lexaria Bioscience Corp ("Lexaria", or the "Company") is a global biotech leader in developing and implementing advanced technologies to better deliver Active Pharmaceutical Ingredients ("APIs") into the human body for faster an
Read more →LEXXLexaria Announces 2 nd Tranche Closing of Non-Brokered Private Placement Kelowna, British Columbia
Lexaria Announces 2nd Tranche Closing of Non-Brokered Private Placement Kelowna, British Columbia- November 29, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has closed the secon
Read more →LEXXLexaria Announces Closing of Non-Brokered Private Placement Kelowna, British Columbia
Lexaria Announces Closing of Non-Brokered Private Placement Kelowna, British Columbia- November 14, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has closed the first tranche of
Read more →LEXXLexaria Bioscience and Hill Street Beverage Co. Enter Global Manufacturing & Licensing Partnership Hill Street Licensed to Offer DehydraTECH Products, Ingredients, and Infused Beverages Worldwide. Kelowna, British Columb
Lexaria Bioscience and Hill Street Beverage Co. Enter Global Manufacturing & Licensing Partnership Hill Street Licensed to Offer DehydraTECH Products, Ingredients, and Infused Beverages Worldwide. Kelowna, British Columbia, and Toronto, Ontario - July 24, 2019 - Lexaria Bioscie
Read more →LEXXLexaria Bioscience Enters CBD Beverage License Agreement with Nic's Beverages Kelowna, British Columbia
Lexaria Bioscience Enters CBD Beverage License Agreement with Nic's Beverages Kelowna, British Columbia - July 10, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has entered a definitiv
Read more →LEXXLexaria Bioscience Announces new DehydraTECH Innovation, Files New Patents New Enhanced DehydraTECH TM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulatio
Lexaria Bioscience Announces new DehydraTECH Innovation, Files New Patents New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations. Kelowna, British Columbia - June 4, 2019 - Lexaria Bios
Read more →LEXXLexaria's DehydraTECH TM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations The DehydraTECH formulation delivered measurable quantities of cannabidiol ("CBD") into
Lexaria's DehydraTECHTM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations The DehydraTECH formulation delivered measurable quantities of cannabidiol ("CBD") into blood in as little as 2 minutes; Lexaria's technolog
Read more →LEXXLexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company Kelowna, British Columbia
Lexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company Kelowna, British Columbia - May 7, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has e
Read more →LEXXLexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services Kelowna, BC
Lexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services Kelowna, BC - April 15, 2019 - Lexaria Bioscience Corp. (CNSX: LXX) (OTCQB: LXRP) ("Lexaria" or the "Company") announces it has retained Oak Hill Financial Inc. ("Oak Hill") to provide inve
Read more →LEXXLexaria Bioscience Renews Contracts with Senior Management and Cancels Options. Kelowna, British Columbia
Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options. Kelowna, British Columbia - April 9, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has successfully nego
Read more →LEXXLexaria Bioscience Begins Largest Cannabinoid R&D Program in its History Kelowna, British Columbia
Lexaria Bioscience Begins Largest Cannabinoid R&D Program in its History Kelowna, British Columbia March 20, 2019 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces that work has commenced on its largest-eve
Read more →LEXXLexaria Warrant Exercises Kelowna, British Columbia
Lexaria Warrant Exercises Kelowna, British Columbia - January 25, 2019 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received funds from the exercise of warrants. Lexaria has received US$10
Read more →LEXXLexaria Bioscience Announces Partnership with Altria to Fund Research and Development of DehydraTECH Technology for Oral Nicotine Lexaria Nicotine LLC and a subsidiary of Altria Group, Inc. have entered into a definitive
Lexaria Bioscience Announces Partnership with Altria to Fund Research and Development of DehydraTECH Technology for Oral Nicotine Lexaria Nicotine LLC and a subsidiary of Altria Group, Inc. have entered into a definitive investment agreement. The Altria investment will f
Read more →LEXXLexaria Bioscience Issues Options Kelowna, British Columbia
Lexaria Bioscience Issues Options Kelowna, British Columbia - December 14, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the following option award. As a result of a new staffing position bei
Read more →LEXXLexaria Bioscience Expands Staff, Issues Options Kelowna, British Columbia
Lexaria Bioscience Expands Staff, Issues Options Kelowna, British Columbia - December 7, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the following updates. The Company continues to hire add
Read more →LEXXLexaria Bioscience Submits Application to Health Canada for Research License and Appoints Chief Legal Officer Kelowna, British Columbia
Lexaria Bioscience Submits Application to Health Canada for Research License and Appoints Chief Legal Officer Kelowna, British Columbia - November 26, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, annou
Read more →LEXXLexaria Bioscience Launches ChrgD+ Kelowna, British Columbia
Lexaria Bioscience Launches ChrgD+ Kelowna, British Columbia - November 13, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the launch of ChrgD+, a water-soluble, ready-mix hemp supplement powde
Read more →LEXXLexaria Bioscience Announces Increased Size and Closing of Private Placement Kelowna, British Columbia
Lexaria Bioscience Announces Increased Size and Closing of Kelowna, British Columbia October 31, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces that due to strong demand it has increased the size
Read more →LEXXLexaria Bioscience Arranges Private Placement Financing to Fund New Laboratory Kelowna, British Columbia
Lexaria Bioscience Arranges Private Placement Financing to Kelowna, British Columbia October 16, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces it has arranged a non-brokered private placement fo
Read more →LEXXLexaria Bioscience Creates and Brands Subsidiary Companies Kelowna, British Columbia
Lexaria Bioscience Creates and Brands Subsidiary Companies Kelowna, British Columbia October 10, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, is pleased to announce it has completed the creation of four
Read more →LEXXLexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance Kelowna, British Columbia
Lexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance Kelowna, British Columbia September 7, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces strateg
Read more →LEXXLexaria Bioscience Announces Positive Blood-Brain-Barrier Results Lexaria s technology delivered 195% more nicotine across the blood-brain-barrier conceptually allowing for smaller micro doses in accordance with developi
Lexaria Bioscience Announces Positive Blood-Brain-Barrier Lexaria s technology delivered 195% more nicotine across the blood-brain-barrier conceptually allowing for smaller micro doses in accordance with developing FDA policies. Lexaria s formulation was 4x faster at reaching
Read more →LEXXLexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing Delivery Measured Within Minutes Nicotine, in an edible form, delivered to blood plasma within minutes after dosing. Statistically significant
Lexaria Bioscience Announces Further Advancement of Edibles Delivery Measured Within Minutes Nicotine, in an edible form, delivered to blood plasma within minutes after dosing. Statistically significant positive in vivo results (n=40; two groups of 20 animals). 90.2% greater
Read more →LEXXLexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages Kelowna, British Columbia and Toronto, Ontario
Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages Kelowna, British Columbia and Toronto, Ontario July 31, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP; CSE: LXX; the Company or Lexaria ), a drug delivery platform i
Read more →LEXXLexaria Announces 2018 AGM Results and Corporate Update Kelowna, British Columbia
Lexaria Announces 2018 AGM Results and Corporate Update Kelowna, British Columbia July 3, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ) announces the results of the 2018 Annual General and Special Meeting. All motions were passed. To Elect D
Read more →LEXXLexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders Kelowna, British Columbia
Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders Kelowna, British Columbia June 29, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Compa
Read more →LEXXLexaria Announces Exercises of Existing Warrants and Options Kelowna, British Columbia
Lexaria Announces Exercises of Existing Warrants and Options Kelowna, British Columbia June 19, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ) announces warrant and option transactions. Lexaria announces it has received US$30,000 from the ex
Read more →LEXXLexaria Announces Exercises of Existing Warrants, Enters Consulting Agreement Kelowna, British Columbia
Lexaria Announces Exercises of Existing Warrants, Enters Consulting Agreement Kelowna, British Columbia May 28, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ) announces warrant Lexaria announces it has received US$63,000 from the exercise of
Read more →LEXXLexaria Bioscience Corp. Receives New Granted Patents Kelowna, British Columbia
Lexaria Bioscience Corp. Receives New Granted Patents Kelowna, British Columbia May 23, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces it has received notifications that it has received two new U
Read more →LEXXLexaria Announces LOI with Hill Street Beverage Co. for Cannabis Infused Alcohol-Free Beer and Wine Kelowna, British Columbia
Lexaria Announces LOI with Hill Street Beverage Co. Cannabis Infused Alcohol-Free Beer and Wine Kelowna, British Columbia April 27, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces that it has ente
Read more →LEXXLexaria Announces Human Clinical Study on CBD Absorption Underway Kelowna, British Columbia
Lexaria Announces Human Clinical Study on CBD Absorption Kelowna, British Columbia April 23, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, is pleased to announce that it has commenced a clinical study in
Read more →LEXXLexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology Kelowna, British Columbia
Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology Kelowna, British Columbia April 17, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, is pleased to announce positive topl
Read more →LEXXLexaria Bioscience Corp. Receives New U.S. Patent Allowance for Cannabinoid Delivery and Updates its Expanding Patent Portfolio Kelowna, British Columbia
Lexaria Bioscience Corp. Receives New U.S. Patent Allowance Delivery and Updates its Expanding Patent Portfolio Kelowna, British Columbia April 11, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces
Read more →LEXXLexaria Announces Exercises of Existing Warrants, Enters Investor Relations Agreement Kelowna, British Columbia
Lexaria Announces Exercises of Existing Warrants, Enters Investor Relations Agreement Kelowna, British Columbia - March 23, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces warrant transactions. Lexaria announces it has received US
Read more →LEXXLexaria Files New Patent Application for Enhanced Transdermal Delivery System Kelowna, British Columbia
Lexaria Files New Patent Application for Enhanced Transdermal Kelowna, British Columbia March 20, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, is pleased to announce it has filed a new patent application
Read more →LEXXLexaria and Neutrisci Enter Global Licensing Agreement Kelowna, British Columbia
Lexaria and Neutrisci Enter Global Licensing Agreement Kelowna, British Columbia February 26, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ) a drug delivery platform innovator, announces it has entered an agreement with NeutriSci Internationa
Read more →LEXXLexaria Announces Exercises of Existing Warrants. Kelowna, British Columbia
Lexaria Announces Exercises of Existing Warrants. Kelowna, British Columbia February 2, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ) announces warrant transactions. Lexaria announces it has received US$17,400 from the exercise of warrants
Read more →LEXXLexaria Enters Licensing Agreement with Canadian Cannabis Chocolate Manufacturer Kelowna, British Columbia
Lexaria Enters Licensing Agreement with Canadian Cannabis Chocolate Manufacturer Kelowna, British Columbia January 25, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ) a drug delivery platform innovator, announces it has entered a definitive te
Read more →LEXXLexaria Upgrades to the OTCQX Market Kelowna, British Columbia
Lexaria Upgrades to the OTCQX Market Kelowna, British Columbia January 4, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces it has qualified and is now trading on the OTCQX Best Market, operated by
Read more →LEXXLexaria Bioscience Announces New Research Including Cannabinoid Topical Creams and Nicotine Edibles Kelowna, British Columbia
Lexaria Bioscience Announces New Research Including Cannabinoid Topical Creams and Nicotine Edibles Kelowna, British Columbia December 15, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery platform innovator, announces a new top
Read more →LEXXLexaria Bioscience Receives U.S. Patent Award for its DehydraTECH TM Delivery of THC, NSAIDs, Nicotine and Vitamins. Kelowna, British Columbia
Lexaria Bioscience Receives U.S. Patent Award for its DehydraTECHTM Delivery of THC, NSAIDs, Nicotine and Kelowna, British Columbia December 13, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) a drug delivery platform innovator, announces the
Read more →LEXXLexaria Announces Option and Warrant Transactions. Kelowna, British Columbia
Lexaria Announces Option and Warrant Transactions. Kelowna, British Columbia December 1, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) announces various stock, option and warrant transactions. Lexaria announces it has received US$6,733.02 fr
Read more →LEXXLexaria Announces Upcoming Investment Event and Warrant Exercise. Kelowna, British Columbia
Lexaria Announces Upcoming Investment Event and Warrant Kelowna, British Columbia November 27, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) announces it is attending and delivering a presentation at the upcoming 10th annual LD Micro Main Ev
Read more →LEXXFiled by newsfilecorp.com Lexaria Bioscience Acquires 100% Ownership of Poviva Tea LLC. Kelowna, British Columbia
Lexaria Bioscience Acquires 100% Ownership of Poviva Tea LLC. Kelowna, British Columbia November 2, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) a drug delivery platform innovator, announces it has acquired 100% ownership interest in its ma
Read more →LEXXLexaria Announces Upcoming Public Events and Warrant Exercise. Kelowna, British Columbia
Lexaria Announces Upcoming Public Events and Warrant Kelowna, British Columbia September 22, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) announces it will be attending and delivering a presentation at the upcoming Canadian Securities Excha
Read more →LEXXUniversity of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria s TurboCBD TM . Kelowna, British Columbia
University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria s Kelowna, British Columbia August 31, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) announces the world s first clinical
Read more →LEXXLexaria Announces Attendance at Two Cannabis Investment Conferences, and Issues Shares for Debt Kelowna, BC /
Lexaria Announces Attendance at Two Cannabis Investment Conferences, and Issues Shares for Debt Kelowna, BC / August 29, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it is attending and exhibiting at the Investorshub International
Read more →LEXXLexaria Announces Exercised Warrants and Options Kelowna, BC /
Lexaria Announces Exercised Warrants and Options Kelowna, BC / August 16, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has received US$91,443.50 from the exercise of warrants and options previously granted. The stock warrants we
Read more →LEXXNational Research Council and Lexaria Bioscience Commence Laboratory Work Kelowna, British Columbia
National Research Council and Lexaria Bioscience Commence Kelowna, British Columbia July 20, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) announces the start of laboratory work under its collaborative research program with the National Rese
Read more →LEXXLexaria Bioscience Awarded Australian Patent For Cannabinoid Infused Edibles Kelowna, British Columbia
Lexaria Bioscience Awarded Australian Patent For Cannabinoid Kelowna, British Columbia July 18, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) is pleased to announce that the Australian Patent Office has granted patent #2015274698 which prote
Read more →LEXXLEXARIA S APPOINTS NEW ACTING CFO Vancouver, British Columbia
LEXARIA S APPOINTS NEW ACTING CFO Vancouver, British Columbia June 5, 2017 Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) is pleased to announce that its has appointed Allan Spissinger as new acting CFO, Secretary and Allan Spissinger was involved i
Read more →LEXXLEXARIA S AMBARII CORPORATION ANNOUNCES LOI WITH NATURALLY SPLENDID TO DISTRIBUTE CBD MELTS IN JAPAN AND SOUTH KOREA Vancouver, British Columbia
LEXARIA S AMBARII CORPORATION ANNOUNCES LOI WITH NATURALLY SPLENDID TO DISTRIBUTE CBD MELTS IN JAPAN AND SOUTH KOREA Vancouver, British Columbia May 30, 2017 Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) is pleased to announce that its 50%-owned jo
Read more →LEXXLexaria Featured on Television Kelowna, BC /
Lexaria Featured on Television Kelowna, BC / May 18, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) is one of five companies featured on a special BTV episode exploring burgeoning cannabis enterprises. Lexaria s patented technology is showcas
Read more →LEXXLexaria Announces Research on Nonsteroidal Anti-Inflammatory Drugs Kelowna, BC /
Lexaria Announces Research on Nonsteroidal Anti-Inflammatory Kelowna, BC / May 10, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the Company , Lexaria ) announces plans for research and formulation development ( R&D ) on nonsteroidal anti-inflammatory drugs ( NSAIDs
Read more →LEXXLexaria Announces R&D on Nicotine Kelowna, BC /
Lexaria Announces R&D on Nicotine Kelowna, BC / May 4, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the Company , Lexaria ) is announcing new plans to commence nicotine absorption research beginning in the summer of 2017, within its previously announced R&D budget t
Read more →LEXXLexaria Announces Million Dollar Research and Development Program Kelowna, BC /
Lexaria Announces Million Dollar Research and Development Kelowna, BC / May 2, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the Company , Lexaria ) announces a $1 million combined research and development ( R&D ) and intellectual property ( IP ) Lexaria s R&D progra
Read more →LEXXExisting Warrants Exercised for Lexaria Kelowna, BC /
Existing Warrants Exercised for Lexaria Kelowna, BC / April 27, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has received US$242,047.50 from the exercise of warrants previously granted. The stock warrants were exercised at price
Read more →LEXXLexaria Welcomes Canada s Proposed Cannabis Legislation Kelowna, BC /
Lexaria Welcomes Canada s Proposed Cannabis Kelowna, BC / April 18, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the Company , Lexaria ) welcomes the newly proposed Canadian legislation designed to allow for adult legal access to Cannabis (the Cannabis Act ). In lin
Read more →LEXXLexaria and Neutrisci Enter Cannabinoid Joint Venture Kelowna, BC /
Lexaria and Neutrisci Enter Cannabinoid Joint Venture Kelowna, BC / April 10, 2017 / Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) (the Company ) and Neutrisci International Inc ( Neutrisci ) (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed the previously ann
Read more →LEXXExisting Stock Option and Warrant Exercises for Lexaria Kelowna, BC /
Existing Stock Option and Warrant Exercises for Lexaria Kelowna, BC / March 24, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has received US$32,503.90 from the exercise of stock options and warrants previously granted. The stoc
Read more →LEXXLexaria Introduces TurboCBD Brand of High Absorption Full Spectrum Hemp Oil Capsules Kelowna, BC /
Lexaria Introduces TurboCBD Brand of High Absorption Full Spectrum Hemp Oil Capsules Kelowna, BC / March 22, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces the introduction of the TurboCBD brand of technologically enhanced, high abs
Read more →LEXXDesign Phase Underway for Studies to be Conducted by National Research Council and Lexaria Kelowna, BC /
Design Phase Underway for Studies to be Conducted by National Research Council and Lexaria Kelowna, BC / March 14, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces that the formal design phase for studies to be conducted under the mas
Read more →LEXXLexaria Receives Notice of its First Patent to be Granted in Australia for Cannabinoid Infused Edibles Kelowna, BC /
Lexaria Receives Notice of its First Patent to be Granted in Australia for Cannabinoid Infused Edibles Kelowna, BC / February 27, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) is pleased to announce it has received a Notice of Acceptance fro
Read more →LEXXStock Option Exercises and Debt Settlement for Lexaria Kelowna, BC /
Stock Option Exercises and Debt Settlement for Lexaria Kelowna, BC / February 17, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has received US$57,001.80 from the exercise of stock options previously granted. The stock options w
Read more →LEXXLexaria Signs Master Collaborative Research Agreement Kelowna, BC /
Lexaria Signs Master Collaborative Research Agreement Kelowna, BC / February 8, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) ( the Company or Lexaria ), through its wholly owned Canadian subsidiary Lexaria Canpharm Corp., has signed and entered a master collaborativ
Read more →LEXXCEO Clips Features Lexaria on the BNN Channel Kelowna, BC /
CEO Clips Features Lexaria on the BNN Channel Kelowna, BC / January 31, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is currently being featured on CEO Clips airing on BNN. CEO Clips profiles some of the most innovative publicly traded companies in No
Read more →LEXXLexaria Receives US$98,000 from Exercise of Options and Warrants Kelowna, BC /
Lexaria Receives US$98,000 from Exercise of Options and Kelowna, BC / January 26, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has received US$98,004.05 from the exercise of stock options and warrants previously granted. The st
Read more →LEXXLEXARIA AND NEUTRISCI ANNOUNCE SUCCESSFUL CANNABINOID TABLET DEVELOPMENT AND POSITIVE RESULTS FROM INITIAL HUMAN OBSERVATIONAL TRIALS. Kelowna, BC
LEXARIA AND NEUTRISCI ANNOUNCE SUCCESSFUL CANNABINOID TABLET DEVELOPMENT AND POSITIVE RESULTS FROM INITIAL HUMAN Kelowna, BC January 19, 2017 - Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) and NeutriSci International Inc. (the "Company" or "Neutri
Read more →LEXXLexaria Receives US$33,029.25 from Exercise of Options and Warrants Kelowna, BC /
Lexaria Receives US$33,029.25 from Exercise of Options and Warrants Kelowna, BC / January 10, 2017 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has received US$33,029.25 from the exercise of stock options and warrants previously gr
Read more →LEXXLexaria Extends Investor Relations Agreement Kelowna, BC /
Lexaria Extends Investor Relations Agreement Kelowna, BC / December 22, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) announces it has extended the services of Frontier Merchant Capital Group ( Frontier ) with a head office in Toronto, Canada, for a pe
Read more →LEXXLexaria Files International Cannabinoid Patent Applications Kelowna, BC
Lexaria Files International Cannabinoid Patent Kelowna, BC December 19, 2016 - Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) is pleased to announce, following the successful October 26, 2016 issuance of its U.S. Patent No. 9,474,725, Cannabinoid In
Read more →LEXXLexaria Receives US$737,500 from Exercise of Warrants Kelowna, BC /
Lexaria Receives US$737,500 from Exercise of Warrants Kelowna, BC / December 2, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has received US$737,500 from the early exercise warrant incentive program announced on October 27, 201
Read more →LEXXHempco Food and Fibre Inc. to Utilize Lexaria s Patented Technology Kelowna, BC /
Hempco Food and Fibre Inc. to Utilize Lexaria s Kelowna, BC / November 29, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) ( the Company or Lexaria ) is pleased to announce the entry of a letter of intent (the LOI ) for the licensing of its proprietary absorption and p
Read more →LEXXLexaria Enters Memorandum of Understanding Establishing a Joint Venture with NeutriSci International Inc. Kelowna, BC /
Lexaria Enters Memorandum of Understanding Establishing a Joint Venture with NeutriSci International Inc. Kelowna, BC / November 22, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) and NeutrisSci International Inc. ( Neutrisci ) (TSX-V:NU, Fra
Read more →LEXXLexaria Announces Price Cuts on ViPova TM Tea Products. Kelowna, BC /
Lexaria Announces Price Cuts on ViPovaTM Tea Products. Kelowna, BC / November 15, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces dramatic price cuts on all ViPovaTM tea products, just in time for the busiest shopping season of the
Read more →LEXXLexaria Option and Warrant Exercise and Issuance Kelowna, BC /
Lexaria Option and Warrant Exercise and Issuance Kelowna, BC / November 2, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces existing warrant and option exercises. The Company has received payment from one person of US$12,500 to exerc
Read more →LEXXLexaria Bioscience Announces Issuance of U.S. Patent for Cannabinoid Infused Edibles Kelowna, BC
Lexaria Bioscience Announces Issuance of U.S. Patent for Cannabinoid Infused Edibles Kelowna, BC - October 26, 2016 - Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) is pleased to announce the U.S. Patent and Trademark Office ( USPTO ) has issued U.S
Read more →LEXXLexaria Engages Consultants and Issues Options Kelowna, BC /
Lexaria Engages Consultants and Issues Options Kelowna, BC / October 11, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) has retained Mackie Research Capital Corp. to provide market maintenance services for the company in compliance with regul
Read more →LEXXLexaria Appoints New Auditors Kelowna, BC /
Lexaria Appoints New Auditors Kelowna, BC / October 6, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has appointed Davidson and Company, LLP, Chartered Professional Accountants, as its new independent registered public auditing
Read more →LEXXLexaria Closes Final Tranche of Fully Subscribed Financing Kelowna, BC /
Lexaria Closes Final Tranche of Fully Subscribed Financing Kelowna, BC / August 31, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has closed the final tranche of the private placement equity financing announced July 5. The Compa
Read more →LEXXNew LOI Signed to Out-License Lexaria s Technology Kelowna, BC /
New LOI Signed to Out-License Lexaria s Technology Kelowna, BC / August 30, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) ( the Company or Lexaria ) has entered a new letter of intent (LOI) to license its proprietary absorption and palatability enhancing technology f
Read more →LEXXFiled by newsfilecorp.com Lexaria Closes Financing, Enhances Investor Relations Agreement Kelowna, BC /
Lexaria Closes Financing, Enhances Investor Relations Kelowna, BC / August 11, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces it has closed the private placement equity financing announced July 5. The financing was for 1,558,525 equ
Read more →LEXXLexaria Signs Letter of Intent for Second Technology Out-Licensing Agreement including Plans to Enter Clinical Studies Kelowna, BC /
Lexaria Signs Letter of Intent for Second Technology Out-Licensing Agreement including Plans to Enter Clinical Studies Kelowna, BC / August 10, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) ( the Company or Lexaria ) has entered a letter of intent (LOI) to license i
Read more →LEXXLexaria Enters Loan Agreement Kelowna, BC /
Lexaria Enters Loan Agreement Kelowna, BC / July 25, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is entering a loan agreement for the principal amount of US$50,000. The term of the agreement is 15 months, with an interest-free holiday for the first
Read more →LEXXLexaria Engages Respected Consulting and Finance Firms Kelowna, BC /
Lexaria Engages Respected Consulting and Finance Firms Kelowna, BC / July 21, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is pleased to announce it has entered into two agreements with highly respected New York based firms. The first agreement is wit
Read more →LEXXLexaria Receives Notice of Allowance of First Patent by US Patent Office Kelowna, BC /
Lexaria Receives Notice of Allowance of First Patent by US Kelowna, BC / July 12, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is very pleased to announce a watershed event in its advancement as a bioscience company: it has just received its first Not
Read more →LEXXFor Canadian Distribution Only Lexaria Intends to Complete an Equity Financing of US$300,000 Kelowna, BC /
For Canadian Distribution Only Lexaria Intends to Complete an Equity Financing Kelowna, BC / July 5, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the "Company" or "Lexaria") reports its intention to complete a non-brokered private placement financing of 5,000,000 e
Read more →LEXXFiled by newsfilecorp.com Lexaria Closes Financing, Enters Investor Relations Agreement, Issues Options Kelowna, BC /
Lexaria Closes Financing, Enters Investor Relations Agreement, Issues Options Kelowna, BC / June 06, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) announces it has closed the private placement equity financing announced May 31. The financing was for 7
Read more →LEXXFor Canadian Distribution Only Lexaria Intends to Complete an Equity Financing of CDN$100,000 Kelowna, BC /
For Canadian Distribution Only Lexaria Intends to Complete an Equity Financing of Kelowna, BC / May 31, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the "Company" or "Lexaria") reports its intention to complete a non-brokered private placement financing of 700,000
Read more →LEXXFiled by newsfilecorp.com Definitive Technology Licensing Agreement Reached Kelowna, BC /
Definitive Technology Licensing Agreement Kelowna, BC / May 20, 2016 / Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is very pleased to announced it has entered into the definitive agreement first announced in a Letter of Intent dated March 22, 2016, to licen
Read more →LEXXFiled by newsfilecorp.com Lexaria Confirms Name Change Kelowna, BC /
Lexaria Confirms Name Change Kelowna, BC / May 9, 2016 / Lexaria Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides the following update. Lexaria confirms that the name change to Lexaria Bioscience Corp has occurred and the that stock is expected to begin trading with the n
Read more →LEXXFiled by newsfilecorp.com Lexaria Announces Change of CFO and Director, and Corporate Update Kelowna, BC /
Lexaria Announces Change of CFO and Director, and Corporate Kelowna, BC / April 27, 2016 / Lexaria Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides the following update. Ms. Bal Bhullar is resigning as CFO and Director of Lexaria effective April 29. Bal has been CFO of Le
Read more →LEXXFiled by newsfilecorp.com Lexaria Closes Tranche of Financing and Issues Shares to President KELOWNA, BC
Lexaria Closes Tranche of Financing and Issues Shares to KELOWNA, BC April 15, 2016 - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has closed a tranche of the Equity financing announced on February 18 for gross proceeds of Each e
Read more →LEXXFiled by newsfilecorp.com Lexaria Closes First Tranche of Financing and Reports Results of
Lexaria Closes First Tranche of Financing and Reports KELOWNA, BC March 29, 2016 - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has closed the first tranche of the Convertible Debenture financing announced on February 18 for gros
Read more →LEXXFiled by newsfilecorp.com Lexaria Announces Groundbreaking Technology Licensing Agreement Kelowna, BC /
Lexaria Announces Groundbreaking Technology Licensing Kelowna, BC / March 22, 2016 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is very pleased to announced it has effected a Letter of Intent to license its patent pending technology for the purpose of entering the U
Read more →LEXXFiled by newsfilecorp.com Lexaria Operations Update Kelowna, BC /
Lexaria Operations Update Kelowna, BC / March 8, 2016 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides an update on operations. The centerpiece of Lexaria s uniqueness is its patent pending technology that enables higher rates of absorption of certain molecules
Read more →LEXXFiled by newsfilecorp.com Lexaria Proposes to Change Name to Lexaria Bioscience Corp Kelowna, BC /
Lexaria Proposes to Change Name to Lexaria Bioscience Corp Kelowna, BC / February 19, 2016 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) announces that at the Annual General Meeting expected to be held March 23, 2016, the Company proposes to change its name to Lexaria
Read more →LEXXFiled by newsfilecorp.com Lexaria Signs Distribution Agreement with Telluride Coffee Kelowna, BC /
Lexaria Signs Distribution Agreement with Telluride Coffee Kelowna, BC / January 28, 2016 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is pleased to announce it has signed a sales distribution agreement with Telluride Coffee Roasters, LLC (TCR) TCR is a wholesale co
Read more →LEXXFiled by newsfilecorp.com Lexaria's Technology Demonstrates Positive Test Results for Nitric Oxide Kelowna, BC /
Lexaria's Technology Demonstrates Positive Test Results for Nitric Oxide Kelowna, BC / January 20, 2016 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the "Company") is very pleased to announce study data from human subjects demonstrating significant elevation of systemic nitric oxide
Read more →LEXXFiled by newsfilecorp.com BUYINS.NET Consults to Lexaria Corp to Surveil Short Sellers and Market Makers. Approximately 26 Million Total Shares Shorted Since August 2009 Short Squeeze Expected When Stock Is Above $0.192
BUYINS.NET Consults to Lexaria Corp to Surveil Short Sellers Approximately 26 Million Total Shares Shorted Since August 2009 Short Squeeze Expected When Stock Is Above $0.192 SqueezeTrigger Price KELOWNA, BC / ACCESSWIRE / January 15, 2016 / Lexaria Corp. (LXRP) (CNSX:LXX)
Read more →LEXXFiled by newsfilecorp.com Lexaria Studies Nitric Oxide Levels in Human Subjects Kelowna, BC /
Lexaria Studies Nitric Oxide Levels in Human Subjects Kelowna, BC / January 13, 2016 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is pleased to announce it has commissioned a study of nitric oxide levels in humans, as a biomarker for absorption of cannabidiol. The s
Read more →LEXXFiled by newsfilecorp.com Lexaria Forward Stock Split KELOWNA, BC
Lexaria Forward Stock Split KELOWNA, BC-- December 16, 2015 - Lexaria Corp. (OTCQB: LXRPD) (CNSX: LXX) (the "Company" or "Lexaria") confirms the earlier announced Lexaria forward stock split has taken place and the company s shares begin trading on a post-split basis today at
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria files Additional New Patent Pendings Kelowna, BC
Lexaria files Additional New Patent Pendings Kelowna, BC December 14, 2015 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces it has initiated the simultaneous filing of two new U.S. provisional patent applications at the U.S. Patent and Trademark O
Read more →LEXXFiled by newsfilecorp.com Lexaria Enters Investors Relations Contract with RADIUS KELOWNA, BC
Lexaria Enters Investors Relations Contract with KELOWNA, BC-- December 14, 2015 - Lexaria Corp. (OTCQB: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") has signed an Investor Relations and media coverage services agreement with RADIUS Consulting, initially on a 45-day trial b
Read more →LEXXFiled by newsfilecorp.com Financing Close KELOWNA, BC
KELOWNA, BC December 10, 2015 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has closed the Private Placement financing announced on September 18 for gross proceeds of Lexaria will issue 500,000 common shares at US$0.18 and 250,000 full war
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Forward Stock Split Kelowna, BC
Lexaria Forward Stock Split Kelowna, BC December 7, 2015 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") further to an earlier announcement, the Company announces the earlier disclosed forward stock split of 1.1 new shares for every existing common share h
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria and ViPova TM Holiday SALE Kelowna, BC
Lexaria and ViPovaTM Holiday SALE Kelowna, BC November 25, 2015 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces its first-ever Holiday blowout sale, just in time for the busiest shopping days of The Holiday sale is effective immediately: all ViP
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Products SOLD OUT in Vegas; Coffee and Cocoa Introduction. Kelowna, BC
Lexaria Products SOLD OUT in Vegas; Coffee and Cocoa Introduction. Kelowna, BC November 17, 2015 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces an overwhelmingly positive response to the new Lexaria Energy Protein Bar at its unveiling at three
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Protein Bar Available Now Kelowna, BC
Lexaria Protein Bar Available Now Kelowna, BC November 3, 2015 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces the brand new Lexaria Energy10 Protein Bar is in stock and available for sale now at a new website: www.lexariaenergyfoods.com. Beginn
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Announces Product Update and International Expansion Kelowna, BC
Lexaria Announces Product Update and International Expansion Kelowna, BC October 8, 2015 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is pleased to announce that the manufacturing process to infuse active hemp oil utilizing Lexaria s patent pending tech
Read more →LEXXFiled by newsfilecorp.com Lexaria, Corp. to Present on Cannabis Investor Webcast Tomorrow Kelowna, BC /
Lexaria, Corp. to Present on Cannabis Investor Webcast Kelowna, BC / October 7, 2015 / Lexaria, Corp. (LXRP) (CSE: LXX) a food sciences company is pleased to announce that John Docherty, President will be presenting on the Cannabis Investor Webcast (www.cannawebcast.com) on T
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Energy Protein Bar Available November 3 Kelowna, BC
Lexaria Energy Protein Bar Available November 3 Kelowna, BC October 6, 2015 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces the brand new Lexaria Energy10 Protein Bar will be in stock and available for sale in just four weeks: on November 3, 2015
Read more →LEXXFiled by newsfilecorp.com Lexaria Partners with MJIC Media For Media Outreach VANCOUVER
Lexaria Partners with MJIC Media For Media Outreach VANCOUVER, Sept. 23, 2015 /Access Wire/ Lexaria Corp. (OTCQB: LXRP, CSE: LXX), a food sciences company focused on food products incorporating legal full spectrum bioavailability enhanced hemp oil, today announced that it has
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Ted McKechnie Joins Lexaria Board of Directors Kelowna, BC
Ted McKechnie Joins Lexaria Board of Directors Kelowna, BC September 16, 2015 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is happy to welcome Mr. Ted McKechnie to its Board of Directors, effective immediately. Ted is a senior entrepreneurial executive
Read more →LEXXFiled by newsfilecorp.com Lexaria's Technology Achieves Cannabidiol Absorption Rate 499% Greater Than Baseline in Laboratory Testing Kelowna, BC /
Lexaria's Technology Achieves Cannabidiol Absorption Rate 499% Greater Than Baseline in Laboratory Testing Kelowna, BC / August 24, 2015 / Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company") is very pleased to announce potential industry-changing achievements in enhanced ga
Read more →LEXXFiled by newsfilecorp.com Lexaria Issues Shares as per Management Contract Kelowna, BC /
Lexaria Issues Shares as per Management Contract Kelowna, BC / August 17, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) announces it has cancelled the 500,000 restricted common shares issued on July 22, 2015, as per an existing management consulting contract, to
Read more →LEXXFiled by newsfilecorp.com Lexaria Introduces NEW ViPova TM Prodcuts Kelowna, BC /
Lexaria Introduces NEW ViPovaTM Kelowna, BC / August 12, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is pleased to announce a suite of new ViPovaTM products available for purchase immediately. The new products all utilize Lexaria s patent-pending technology de
Read more →LEXXFiled by newsfilecorp.com Lexaria Hires Investor Relations Firm Kelowna, BC /
Lexaria Hires Investor Relations Firm Kelowna, BC / August 11, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) announces it has hired Blue Ocean Advisors of San Diego, CA to assist in communicating its corporate, financial and long-term investment messages to shar
Read more →LEXXFiled by newsfilecorp.com Laboratory Testing and Sales Distribution Update Kelowna, BC /
Laboratory Testing and Sales Distribution Update Kelowna, BC / July 28, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides the following information to update both the status of the ongoing laboratory testing; and, of progress with sales and On May 20, Lexar
Read more →LEXXFiled by newsfilecorp.com Lexaria Lowers Prices Kelowna, BC /
Lexaria Lowers Prices Kelowna, BC / July 14, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is pleased to announce, effective immediately, new lower pricing for all its existing products. The new pricing is the result of greater manufacturing efficiencies as a re
Read more →LEXXFiled by newsfilecorp.com Lexaria Announces Definitive Agreement Kelowna, BC /
Lexaria Announces Definitive Agreement Kelowna, BC / June 26, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) announces it has signed the Definitive Agreement on the sale of its 49% interest in the Burlington MMPR application along with its joint venture partner E
Read more →LEXXFiled by newsfilecorp.com Supreme Court of Canada Rules in Favour of Cannabis Edibles Kelowna, BC /
Supreme Court of Canada Rules in Favour of Cannabis Edibles Kelowna, BC / June 23, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides the following information related to the Supreme Court of Canada ruling in the Owen Smith case. This case was related to the
Read more →LEXXFiled by newsfilecorp.com Lexaria Focuses on Technology; Sells Burlington MMPR License Application Kelowna, BC /
Lexaria Focuses on Technology; Sells Burlington MMPR License Kelowna, BC / June 12, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides the following update related to the Burlington MMPR license application. Lexaria has made significant gains in developing a
Read more →LEXXFiled by newsfilecorp.com Lexaria Files U.S. Utility and International Patent Applications Encompassing Expanded Uses for Its Core Technology Kelowna, BC /
Lexaria Files U.S. Utility and International Patent Encompassing Expanded Uses for Its Core Technology Kelowna, BC / June 11, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) ( Lexaria or the Company ) provides the following information regarding existing and new patents pending.
Read more →LEXXFiled by newsfilecorp.com Lexaria Enters Services Contract with TDM Financial KELOWNA, BC--(Marketwired
Lexaria Enters Services Contract with TDM Financial KELOWNA, BC--(Marketwired June 8, 2015) - Lexaria Corp. (OTCQB: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") has signed an IR/PR services agreement with TDM Financial valid for the next 60 days. Lexaria expects to receive
Read more →LEXXFiled by newsfilecorp.com Lexaria Updates Sales Channels Efforts Kelowna, BC /
Lexaria Updates Sales Channels Efforts Kelowna, BC / June 5, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides the following information regarding sales channels that the Company is developing. Lexaria has to date sold small but increasing amounts of ViPov
Read more →LEXXFiled by newsfilecorp.com Bioavailability Testing to Commence On Lexaria s Patent-Pending Technology Kelowna, BC /
Bioavailability Testing to Commence On Lexaria s Patent-Pending Technology Kelowna, BC / May 20, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is pleased to announce it has engaged Absorption Systems LP in the USA, to begin third party in vitro tests using a hum
Read more →LEXXFiled by newsfilecorp.com Lexaria Intellectual Property Update Kelowna, BC /
Lexaria Intellectual Property Update Kelowna, BC / May 15, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides the following update and information regarding its patent-pending technology; how it relates to the delivery of certain active ingredients such as C
Read more →LEXXFiled by newsfilecorp.com Lexaria Closes Financing and announces Conference Participation KELOWNA, BC
Lexaria Closes Financing and announces Conference KELOWNA, BC May 15, 2015 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has closed the Private Placement financing announced on April 17 for gross proceeds of US$500,000. Lexaria will issue
Read more →LEXXFiled by newsfilecorp.com Lexaria Launches New Corporate Website Kelowna, BC /
Lexaria Launches New Corporate Website Kelowna, BC / April 30, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the "Company") announces the launch of a brand new corporate website at www.lexariaenergy.com. Lexaria invites everyone to visit our website and learn about our excitin
Read more →LEXXFiled by newsfilecorp.com Lexaria s ViPova TM Tea Available Soon at Amazon.com Kelowna, BC /
Lexaria s ViPovaTM Tea Available Kelowna, BC / April 8, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is very pleased to announce that ViPovaTM tea will soon be available for sale at Amazon.com and other online retailers. We expect to have ViPova tea available f
Read more →LEXXFiled by newsfilecorp.com Lexaria Updates Operations Kelowna, BC /
Lexaria Updates Operations Kelowna, BC / April 7, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) provides the following updates. Lexaria is pleased to announce the manufacturing of delicious ViPovaTM tea in conventional tea-bags has begun: over 80% of all tea so
Read more →LEXXFiled by newsfilecorp.com Lexaria s New President From BioPharmaceutical Industry Kelowna, BC /
Lexaria s New President From BioPharmaceutical Kelowna, BC / March 26, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is pleased to announce an important addition to the Lexaria management team. John Docherty, M.Sc. is the new President of Lexaria Corp, replacin
Read more →LEXXFiled by newsfilecorp.com Lower Prices for ViPova TM Tea Due to Production Efficiencies Kelowna, BC /
Lower Prices for ViPovaTMTea Due to Production Efficiencies Kelowna, BC / March 24, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) announces an immediate reduction in price for ViPovaTM CBD-infused tea from US$129 to US$99. Efficiencies in the production process
Read more →LEXXFiled by newsfilecorp.com Lexaria, Corp. to Present at Cannabis Investor Webcast Kelowna, BC /
Lexaria, Corp. to Present at Cannabis Investor Webcast Kelowna, BC / March 11, 2015 / Lexaria, Corp. (LXRP) (CSE:LXX) will be presenting at the Cannabis Investor Webcast tomorrow: Thursday, March 12, 2015 at 5:00 PM ET (2 PM Pacific). "We're excited that Lexaria, Corp. has de
Read more →LEXXFiled by newsfilecorp.com Lexaria Letter From the President Kelowna, BC /
Lexaria Letter From the President Kelowna, BC / February 24, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) is pleased to provide a Letter From the President for all its stakeholders. Lexaria has posted at its website www.lexariaenergy.com a letter from the presi
Read more →LEXXFiled by newsfilecorp.com ViPova TM by Lexaria Launches National Sales Initiative Kelowna, BC /
ViPovaTM by Lexaria Launches National Sales Initiative Kelowna, BC / February 23, 2015 / Lexaria, Corp. (LXRP) (CSE:LXX) (the Company ) announces that ViPovaTM by Lexaria has launched a national US initiative designed to assist Americans to simultaneously achieve two importa
Read more →LEXXFiled by newsfilecorp.com Lexaria Hires National Sales Strategist and Sponsors First Sales Event Kelowna, BC /
Lexaria Hires National Sales Strategist and Sponsors First Sales Event Kelowna, BC / February 13, 2015 / Lexaria, Corp. (LXRP) (CSE:LXX) (the "Company") announces that ViPovaTM by Lexaria is sponsoring its first major sales event; and also announces the hiring of a National Sale
Read more →LEXXFiled by newsfilecorp.com Lexaria Maintains OTCQB Marketplace Status Kelowna, BC /
Lexaria Maintains OTCQB Marketplace Status Kelowna, BC / February 2, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the Company ) announces the Company has submitted all the mandatory documents and has successfully met all of the requirements for continued listing and trading
Read more →LEXXFiled by newsfilecorp.com Lexaria announces ViPova TM Website for CBD Research and Direct Tea Sales Kelowna, BC /
Lexaria announces ViPovaTM Website for CBD Research and Direct Tea Sales Kelowna, BC / January 15, 2015 / Lexaria, Corp. (LXRP) (CSE:LXX) (the Company ) announces that ViPovaTM by Lexaria has launched a new website at www.vipova.com The new site is live and contains research
Read more →LEXXFiled by newsfilecorp.com Lexaria Commissions Cannabinoid Education Series Kelowna, BC /
Lexaria Commissions Cannabinoid Education Series Kelowna, BC / January 8, 2015 / Lexaria, Corp. (LXRP) (CSE:LXX) (the Company ) has engaged Michelle Reillo, PhD, to write a series of manuals providing guidance to both consumers of CBD and practitioners who advise patients in
Read more →LEXXFiled by newsfilecorp.com Lexaria announces Name Change of PoViva Tea to ViPova TM Tea, and Provides Information on Hemp-Based Industry Kelowna, BC / December17, 2014 / Lexaria, Corp. (LXRP) (CSE:LXX) (the "Company") ann
Lexaria announces Name Change of PoViva Tea to ViPovaTM Tea, and Provides Information on Hemp-Based Industry Kelowna, BC / December17, 2014 / Lexaria, Corp. (LXRP) (CSE:LXX) (the "Company") announces that, effectively immediately, it's 51%-owned company formerly known as PoViva
Read more →LEXXFiled by newsfilecorp.com ViPova TM by Lexaria Announces New President Kelowna, BC / December 22 , 2014 / Lexaria, Corp. (LXRP) (CSE:LXX) (the "Company"), as part of its broader business transition into the alternative h
ViPovaTM by Lexaria Announces New President Kelowna, BC / December 22 , 2014 / Lexaria, Corp. (LXRP) (CSE:LXX) (the "Company"), as part of its broader business transition into the alternative health industry, is pleased to announce it has hired Tom Ihrke as President of its U.S.
Read more →LEXXLexaria Closes 51% Acquisition of PoViva Tea, LLC Kelowna, BC /
Lexaria Closes 51% Acquisition of PoViva Tea, Kelowna, BC / December 12, 2014 / Lexaria, Corp. (LXRP) (CSE:LXX) (the Company ) is pleased to announce it has closed the 51% acquisition of Poviva Tea, LLC. As the final part of the closing, Lexaria has issued 119,047 restricted
Read more →LEXXFiled by newsfilecorp.com Lexaria Oilfield Sale Completed KELOWNA, BC
Lexaria Oilfield Sale Completed KELOWNA, BC December 10, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce the sale of all its Belmont Lake oil assets for $1.4 million in cash has closed and all money received. Lexaria congratul
Read more →LEXXLexaria Updates Burlington License Application KELOWNA, BC
Lexaria Updates Burlington License Application KELOWNA, BC December 9, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce progress on the Burlington, Ontario MMPR license application. Health Canada has advised our joint venture p
Read more →LEXXFiled by newsfilecorp.com Lexaria Enters Agreement to Sell Belmont Lake Oil Assets KELOWNA, BC
Lexaria Enters Agreement to Sell Belmont Lake Oil KELOWNA, BC December 1, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has entered an agreement to sell all its Belmont Lake oil assets in an all-cash transaction of $1.4 million to Clo
Read more →LEXXFiled by newsfilecorp.com Lexaria and Enertopia Launch Medical Advisory Board KELOWNA, BC
Lexaria and Enertopia Launch Medical Advisory Board KELOWNA, BC-November 20, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce that it and joint venture partner Enertopia Corp (ENRT) have launched a formal Medical Advisory Board to
Read more →LEXXFiled by newsfilecorp.com Lexaria Updates Medical Marijuana and Cannabidiol Policies KELOWNA, BC
Lexaria Updates Medical Marijuana and Cannabidiol Policies KELOWNA, BC November 18, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces new medical marijuana and Cannabidiol (CBD) policies. Broadly speaking, subject to receiving a Canadian MMP
Read more →LEXXFiled by newsfilecorp.com Health & Wellness Business Plan by Lexaria KELOWNA, BC
Health & Wellness Business Plan by Lexaria KELOWNA, BC-November 13, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria"). Lexaria is in the midst of a major corporate transformation that began with our announcement on March 5, 2014, when we made a strategi
Read more →LEXXFiled by newsfilecorp.com Lexaria Continues Transformation Into Alternative Health Sector KELOWNA, BC
Lexaria Continues Transformation Into Alternative Health KELOWNA, BC November 12, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces has entered an agreement and has begun a staged acquisition of a corporation and its expertise in delivering
Read more →LEXXFiled by newsfilecorp.com Lexaria Closes Second Tranche of Financing KELOWNA, BC
Lexaria Closes Second Tranche of Financing KELOWNA, BC September 26, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has closed a second tranche of its Private Placement financing announced on August 9 for gross proceeds of Lexaria will
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE National Medical Marihuana Outreach Plan Kelowna, BC
National Medical Marihuana Outreach Plan Kelowna, BC September 18, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") reports that the joint venture with Enertopia Corp has begun a National Medical Marijuana Awareness and Outreach Strategy headed by Mau
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Health Canada Marijuana License Application Submitted Kelowna, BC
Health Canada Marijuana License Application Kelowna, BC September 17, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") reports that the joint venture with Enertopia Corp has submitted the Health Canada MMPR Licensed Producer application in July 2014,
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Excellent Results at New Lexaria Oil Well Kelowna, BC
Excellent Results at New Lexaria Oil Well Kelowna, BC September 16, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") is very pleased to report excellent oil production rates at the new PPF-12-7 oil well at Belmont Lake, Mississippi. The well is now fl
Read more →LEXXLexaria Announces Responsible Marijuana Policy KELOWNA, BC
Lexaria Announces Responsible Marijuana Policy KELOWNA, BC-August 28, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria" or "our" or "Lexaria CanPharm Corp") announces our new corporate policies regarding the responsible use of medical In Canada, the MMPR
Read more →LEXXProgress at Lexaria's Belmont Lake Oil Field Kelowna, BC
Progress at Lexaria's Belmont Lake Oil Field Kelowna, BC-August 27, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") is pleased to report of new developments at the Belmont Lake oil field in Mississippi. Well PPF-12-7 was drilled in December 2013 but wa
Read more →LEXXFiled by newsfilecorp.com Lexaria Closes First Tranche of Financing KELOWNA, BC
Lexaria Closes First Tranche of Financing KELOWNA, BC August 12, 2014 - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces it has closed the first tranche of its Private Placement financing announced on August 9 for gross proceeds of Lexaria will is
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Corporate Update Kelowna, BC
Kelowna, BC August 5, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is announces that it is in the process of making all the cash and stock payments required to secure its lease of the Burlington marijuana production facility to Dec 9, 2014. This inc
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Issues Stock Options Kelowna, BC
Lexaria Issues Stock Options Kelowna, BC July 24, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces it has issued 625,000 stock options to an advisor and consultants, vesting immediately, with an exercise price of US$0.25. The stock options ex
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Municipal Approval for Lexaria-Enertopia Joint Venture in Burlington, Ontario Kelowna, BC
Municipal Approval for Lexaria-Enertopia Joint Venture in Burlington, Ontario Kelowna, BC-July 14, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is pleased to announce that the production of Medical Marihuana in compliance with Health Canada MMPR regul
Read more →LEXXOverwhelming Support at 2014 Lexaria AGM. Kelowna, BC
Overwhelming Support at 2014 Lexaria AGM. Kelowna, BC June 17, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") today announces that all resolutions were approved and adopted at its Annual General Meeting (AGM) held Re-election of Chris directors was a
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria and Enertopia Update LOI with Signed Definitive Joint Venture Agreement Kelowna, BC
Lexaria and Enertopia Update LOI with Signed Definitive Joint Venture Agreement Kelowna, BC May 29, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces it has signed the definitive Joint Venture agreement as required in the Letter of Intent that
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Announces Second Production Facility and Vendor Intention to Finance up to 3,000,000 Kelowna, BC
Lexaria Announces Second Production Facility and Vendor Intention to Finance up to 3,000,000 Kelowna, BC-May 27, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces it has entered a detailed Letter of Intent with Huntington Property Group Inc, an O
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Appoints Former Chief of Police as Security Consultant Kelowna, BC
Lexaria Appoints Former Chief of Police as Security Consultant Kelowna, BC-May 5, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is pleased to announce the appointment of the Security Consultant for the new Ontario production facility. The former Chief
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Resignation of Director Kelowna, BC
Kelowna, BC April 25, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces the resignation of Dr David DeMartin as Director and Chief Scientific Advisor to the Company, effective immediately. Dr. DeMartini was instrumental in advancing the Belmont
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Adds to Management Team Kelowna, BC
Lexaria Adds to Management Team Kelowna, BC-April 24, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is pleased to announce new Managers joining the Company and assisting in the development and growth of the Ontario marijuana production facility. Mr.
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Welcomes Jeff Paikin to Advisory Board Kelowna, BC
Lexaria Welcomes Jeff Paikin to Advisory Board Kelowna, BC April 14, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is pleased to announce the appointment of a new expert to its Advisory Board. Mr. Jeff Paikin has joined Lexaria s Advisory Board. Mr
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria's First Marijuana Production Facility Kelowna, BC
Lexaria's First Marijuana Production Facility Kelowna, BC-April 10, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces it has entered agreements for its first co-owned and co-managed marijuana production facility in Canada. The facility is compri
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Eliminates 193,333 in Debts Kelowna, BC
Lexaria Eliminates 193,333 in Debts Kelowna, BC-March 31, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is pleased to announce it has eliminated 193,333 in existing debts through the conversion of those debts into equity units priced Lexaria entered i
Read more →LEXXLexaria Welcomes New Medical Marijuana Expert Advisor Kelowna, BC
Lexaria Welcomes New Medical Marijuana Expert Kelowna, BC March 25, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") is pleased to announce the appointment of its first medical marijuana expert to its Advisory Board. Mr Jason Springett has joined Lexar
Read more →LEXXFiled by newsfilecorp.com Lexaria Closes $1,272,000 Financing KELOWNA, BC--(Marketwired
Lexaria Closes $1,272,000 Financing KELOWNA, BC--(Marketwired - Mar 21, 2014) - Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce it has closed its Private Placement financing announced on March 5 for gross proceeds of $1,272,000. The
Read more →LEXXFiled by newsfilecorp.com Lexaria Launches Awareness Program VIA AGORACOM KELOWNA, BC--(Marketwired
Lexaria Launches Awareness Program VIA AGORACOM KELOWNA, BC--(Marketwired - Mar 12, 2014) - Lexaria Corp. (OTCQB: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") is pleased to announce it has signed a Market Awareness agreement with Agoracom. Lexaria will receive significant e
Read more →LEXXLexaria Enters Social Media Contract Kelowna, BC
Lexaria Enters Social Media Contract Kelowna, BC March 10, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces that it has entered into a one year contract with Stuart Gray to provide Social Media Marketing. Mr. Gray has been in the social media
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Enters Joint Venture with Enertopia Corp in Medical Marihuana Industry Kelowna, BC
Lexaria Enters Joint Venture with Enertopia Corp in Medical Marihuana Industry Kelowna, BC March 5, 2014 - Lexaria Corp. (LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") reports that its board of directors has decided to make a strategic entry into the medical marihuana b
Read more →LEXXFiled by newsfilecorp.com
February 28, 2014 Trading Symbol: LXRP-OTCQB LXX-CSE (Kelowna, BC: February 28, 2014) - Lexaria Corp. (the "Company or Lexaria") announces that Mr. Dustin Elford has resigned as a Director, in order to concentrate on other commitments. Lexaria thanks Mr. Elford for his contr
Read more →LEXXSuccessful New Oil Well Kelowna, BC
Successful New Oil Well Kelowna, BC December 6, 2013 - Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") is pleased to report that the newly drilled PPF-12-7 well at Belmont Lake has reached total depth and sidewall core analysis indicates approximately 20 fe
Read more →LEXXLexaria Corp. Announces Permits Received for Drilling of New Well Kelowna, BC
Lexaria Corp. Announces Permits Received for Drilling of New Well Kelowna, BC November 27, 2013 - Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") reports that the drilling permit has been approved and received for the drilling of the 12-7 well at Belmont L
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Debt Successfully Refinanced Kelowna, BC
Debt Successfully Refinanced Kelowna, BC November 13, 2013 - Lexaria Corp (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") announces that it has refinanced and extended repayment terms on all debt that was otherwise due to mature in Lexaria has entered into debt amendment
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE New Well To Be Drilled at Belmont Lake Field Kelowna, BC
New Well To Be Drilled at Belmont Lake Field Kelowna, BC November 4, 2013 - Lexaria Corp (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") is pleased to report that work will begin soon for a new oil well to be drilled at the Belmont Lake Field, Mississippi. This is the fi
Read more →LEXXFiled by newsfilecorp.com NEWS RELEASE Lexaria Announces Well Recompletion Kelowna, BC
Lexaria Announces Well Recompletion Kelowna, BC October 3, 2013 - Lexaria Corp (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") is pleased to report that work is scheduled to begin next week on a recompletion procedure of the 12-4 well located at Belmont Lake, Mississippi
Read more →LEXXLexaria Corp. Provides Mississippi Oil Field Update Kelowna, BC
Lexaria Corp. Provides Mississippi Oil Field Kelowna, BC September 23, 2013 - Lexaria Corp (LXRP-OTCQB) (LXX-CNSX) (the "Company" or "Lexaria") reports oil production rates and oil workover operations that are expected to increase Lexaria expects to conduct a major work-over
Read more →LEXXLexaria Corp. Provides Third Quarter Results Kelowna, BC
Lexaria Corp. Provides Third Quarter Results Kelowna, BC September 12, 2013 - (LXRP-OTCBB) (LXX-CNSX) Lexaria Corp. announces that it has filed its third quarter financial results to July 31, 2013 via Form 10Q on EDGAR in the USA, and (All figures in US currency, for the nine
Read more →LEXXLexaria Corp. Engages Corporate Communications Firm Kelowna, BC
Lexaria Corp. Engages Corporate Communications Kelowna, BC August 26, 2013 - (LXRP-OTCBB) (LXX-CNSX) Lexaria Corp. announces that it has entered into an agreement with Carmel Advisors LLC, of San Diego, CA, for the purposes of public relations and corporate communications ser
Read more →LEXXLexaria Corp. Grants Options Kelowna, BC
Lexaria Corp. Grants Options Kelowna, BC June 18, 2013 - (LXRP-OTCBB) (LXX-CNSX) Lexaria Corp. announces that it has granted 500,000 stock options effective June 18th, 2013, as per the 2010 equity compensation plan. The exercise price is US$0.10 and the options vest immediate
Read more →LEXXLexaria Corp. Annual General Meeting Results Vancouver
Lexaria Corp. Annual General Meeting Results Vancouver May 1, 2013 - (LXRP-OTCBB) (LXX-CNSX) Lexaria Corp. (the "Company" or "Lexaria") today announces that at its AGM on April 17th, all resolutions passed. On April 17, 2013, the Company had its Annual General Meeting. Certa
Read more →LEXXANNOUNCING CLOSING OF PRIVATE PLACEMENT MD Filed by Filing Services Canada Inc. (403) 717-3898
Trading Symbol: LXRP: OTCBB $228,000 PRIVATE PLACEMENT CLOSED (Vancouver, BC: December 29, 2009) - Lexaria Corp. (the "Company or Lexaria") announces it has closed a private placement of 1,617,752 units at a price of $0.12 per unit for gross proceeds of $194,130. Each unit con
Read more →Competitive Position
How LEXX ranks across every disease it competes inCompetitive Position is a premium feature
See how LEXX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial